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CHAPTER ONE
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Abstract
Plasmodium vivax occurs globally and thrives in both temperate and tropical climates.
Here, we review the evidence of the biological limits of its contemporary distribution
and the global population at risk (PAR) of the disease within endemic countries. We also
review the most recent evidence for the endemic level of transmission within its range
and discuss the implications for burden of disease assessments. Finally, the evidencebase for defining the contemporary distribution and PAR of P. vivax are discussed
alongside a description of the vectors of human malaria within the limits of risk. This
information along with recent data documenting the severe morbid and fatal consequences of P. vivax infection indicates that the public health significance of P. vivax is
likely to have been seriously underestimated.

1. INTRODUCTION
Malaria is a highly significant global public health problem. Its greatest burden is imposed on the world’s poorest countries (Sachs and Malaney,
2002). It is the third leading cause of death from infectious diseases for
children under age of five worldwide (Black et al., 2010) and the fourth
leading cause for all ages (WHO, 2008). After decades of neglect, malaria
control research and financing has experienced a resurgence in recent years
(RBMP, 2008) and targets have been raised by international initiatives aiming for the goal of elimination (Feachem et al., 2009; Chitnis et al., 2010a;
Moonen et al., 2010; Tanner and Hommel, 2010; Tatem et al., 2010; Alonso
et al., 2011). While elimination goals ostensibly address all human malarias, the allocation of funding and resources between the two parasites of
greatest significance, Plasmodium falciparum and Plasmodium vivax, has been
highly disparate. From 2007 to 2009, only 3.1% of all malaria research and
development funding was targeted at P. vivax (PATH, 2011). Plasmodium
vivax is epidemiologically and biologically different to P. falciparum and it
is not, therefore, possible to assume that control methods developed for
falciparum malaria are transferable to vivax malaria (Luxemburger et al.,
1994; Bockarie and Dagoro, 2006; Baird, 2010; Bousema and Drakeley,
2011). Evidence from P. vivax infections in carefully monitored populations
show that vivax malaria should no longer be thought of as a benign and
rarely fatal disease but one that can lead to severe disease and death (Baird,
2007; Price et al., 2007b; Anstey et al., 2009). The reader is referred to an
accompanying review in this thematic volume of Advances in Parasitology
(Chapter 3, Volume 80), which addresses the clinical severity of P. vivax.
The clinical importance of P. vivax, along with its wide geographic distribution extending well beyond the limits of falciparum malaria (Guerra et al.,
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2006a, 2006b, 2010; Gething et al., 2011b) and the challenges it presents for
control (Sattabongkot et al., 2004; Wells et al., 2010), has led to a call for
greater attention to be paid to understanding the global distribution and
burden of this neglected parasite (Baird, 2007; Price et al., 2007b; Mueller
et al., 2009a).
A key information gap impeding P. vivax control and progress towards
elimination has been the lack of geographical estimates of risk (Mendis et al.,
2001; Price et al., 2007b; Malaria Eradication Research Agenda, 2011b).
Assessment of geographic variations in levels of endemicity of the parasite
is essential to estimate the burden of the disease and measure the impact
of control and the feasibility of elimination (Pampana, 1969; Hay et al.,
2008; Tatem et al., 2010). The Malaria Atlas Project (MAP) was founded to
address this evidence gap (Hay and Snow, 2006; Hay et al., 2009; Gething
et al., 2011a), with an initial focus on P. falciparum, and the resulting global
malaria distributions have been used to assess the adequacy and equity in
control funding (Pigott et al., 2012), to inform international policy and
resource allocation (Anonymous, 2009; Feachem et al., 2009; McLaughlin
et al., 2009; World Bank, 2009; Zanzibar Malaria Control Program, 2009;
DFID, 2010; Global Partnership to Roll Back Malaria et al., 2010) and to
estimate the global burden of disease (Patil et al., 2009; Gething et al., 2010a;
Hay et al., 2010b). A suite of modelled spatial data on P. vivax transmission
and endemicity (Guerra et al. 2010; Gething et al. 2012) and P. vivax vectors (Sinka et al., 2010a, 2010b, 2011, 2012) add to this evidence base for
strategic disease-control planning, implementation and monitoring. Here,
for the first time, we bring all these mapped data on P. vivax together in
one place. We explain how these products were generated, their limitations
and their value, and provide an overview for each malaria-endemic region
of the world. We also consider those areas where our lack of geographical
knowledge is particularly acute and would benefit most from concerted
future research efforts. A full review of the methodologies used to generate
each mapped product is also provided at the end of this chapter.

2. T
 HE GLOBAL DISTRIBUTION OF P. VIVAX
INFECTIONS
Plasmodium vivax has the widest geographical distribution of the
human malarias with an estimated 2.49 billion individuals living at risk of
infection in 2010 (Gething et al., 2012). Biological features of P. vivax that
distinguish it from P. falciparum present unique challenges to the control of
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the parasite (Mendis et al., 2001; Sattabongkot et al., 2004;Wells et al., 2010);
in elimination settings, P. vivax is often the ‘last parasite standing’ (Garnham,
1951;Yekutiel, 1960; Pampana, 1969; Wernsdorfer et al., 2009; Tatem et al.,
2010). Plasmodium vivax gametocytes are present earlier in the progression
of a primary or recrudescent infection than P. falciparum (Mendis et al., 2001;
McKenzie et al., 2002), such that the majority of patients have sufficient
gametocytaemia to allow transmission before the infection is diagnosed or
treated (Ratcliff et al., 2007; Awab et al., 2010; Douglas et al., 2010).
Plasmodium vivax gametocytes are transmitted more efficiently to Anopheles
mosquito vectors (Boyd and Kitchen, 1937; Collins et al., 2002) than those
of P. falciparum and are transmissible at lower parasite densities (Sattabongkot
et al., 2004). Within the mosquito, vivax sporozoites develop faster than P.
falciparum and with slightly wider viable temperature ranges, allowing for a
greater geographical distribution (Gething et al., 2011b). In addition, due
to vector bionomics in regions where P. vivax is most prevalent, methods of
control that are broadly effective in reducing P. falciparum transmission, such
as insecticide-treated bed nets (ITNs), show far less success in the control of
P. vivax (Luxemburger et al., 1994; Bockarie and Dagoro, 2006). Plasmodium
vivax malaria is typically carried with lower levels of parasitaemia, making it
relatively difficult to diagnose (Mendis et al., 2001). However, there is evidence that, despite lower blood parasite loads, P. vivax immunity is acquired
more rapidly than P. falciparum and may result in an earlier age-prevalence
peak in areas of high transmission (Mueller et al., 2009a, 2009b). Detailed
reviews regarding the biology (Chapter 2, Volume 80), control (Chapter 6,
Volume 80), and acquired immunity (Chapter 3,Volume 81) of P. vivax are
available elsewhere in this thematic issue of Advances in Parasitology.
Perhaps the most important feature of P. vivax biology is its ability to relapse
in the weeks and months following a primary parasitaemia, via a dormant liver
stage known as the hypnozoite (James, 1931; Coatney, 1976; Garnham, 1989;
Prudencio et al., 2006; Chen et al., 2007; Imwong et al., 2007;White, 2011). It
has long been known that there is significant geographical variation in the rate
at which a ‘strain’ of P. vivax may relapse (Coatney and Cooper, 1948;Winckel,
1955; Garnham et al., 1975). The exact mechanism through which hypnozoite relapses are triggered is unknown (Cogswell, 1992; Prudencio et al., 2006;
Baird, 2009; Mueller et al., 2009a). One theory is that the mechanism is an
adaptive trait of the parasite to sequester or ‘hibernate’ during times when climatic conditions would be inhospitable to the Anopheles vector of the disease
(Shute et al., 1976; Baird and Rieckmann, 2003; White, 2011). This theory is
supported by observations that temperate strains of the parasite tend to exhibit
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longer relapse intervals than tropical strains (Garnham et al., 1975; Shute et al.,
1976; Cogswell, 1992; Collins and Jeffery, 1996; Adak et al., 1998; Baird et al.,
2007; Imwong et al., 2007). Primaquine is currently the only widely available drug with activity on the hypnozoite stage capable of preventing relapse
(Baird and Hoffman, 2004; Galappaththy et al., 2007), but is associated with
haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD)
deficiency (Beutler, 1994; Baird and Hoffman, 2004; Cappellini and Fiorelli,
2008). Primaquine is contraindicated in pregnant women because of the risk
of haemolytic anaemia in the foetus of unknown G6PD status (WHO, 2010a).
The reader is referred to reviews that address relapse (Chapter 2,Volume 80),
treatment (Chapters 4 and 5, Volume 80) and G6PD deficiency (Chapter 4,
Volume 81), which are provided elsewhere in this special issue Advances in
Parasitology. Relapse also has implications for understanding the burden of
P. vivax malaria based on prevalence rates derived from malariometric surveys
and cartographic studies (Patil et al., 2009; Hay et al., 2010b).
To accurately illustrate P. vivax endemicity, it is necessary to incorporate
the distribution of the Duffy-negative phenotype. The varying prevalence
of Duffy negativity in populations throughout the world is a significant
determinant of the distribution of P. vivax (Livingstone, 1984). Duffy-
negative individuals are, for the most part, refractory to P. vivax infection
and the phenotype is found at highest frequencies in Africa, whereas it is
relatively rare elsewhere (Howes et al., 2011). A detailed review of the effect
of Duffy negativity on the epidemiology of P. vivax (Chapter 2,Volume 81)
is provided elsewhere in this series. The influence of Duffy negativity on
P. vivax transmission reinforces the need to differentiate strategies employed
to generate and interpret maps of P. vivax endemicity from those used for
P. falciparum (Hay et al., 2009; Gething et al., 2011a).
Until recently, little work had been done to define the geographic limits and risk of P. vivax infection. The only map including vivax malaria
endemicity was that of Lysenko from 1968 (Lysenko and Semashko, 1968).
As shown in Fig. 1.1, Lysenko defined endemicity as the parasite rate
(PR) in children aged between 2 and 10 years old (hypoendemic <10%,
mesoendemic 11–50%, hyperendemic 51–75%), with the exception of the
holoendemic class (>75%) where the PR was defined in the 1-year age
cohort. The map was derived from a synthesis of historical records and
malariometric indices of all four human malaria parasites: disease and vector
presence and absence records; spleen, parasite, sporozoite and biting rates;
sickle cell incidence; and others (Hay et al., 2004; Gething et al., 2010b).
Lysenko interpolated the data globally to determine the distribution of
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Figure 1.1 The Lysenko map of global malaria endemicity. The map was digitised
from its original source (Lysenko and Semashko, 1968) where endemicity classes were
defined by parasite rate (PR) in children between 2 and 10 years old (hypoendemic
<10%, mesoendemic 11–50%, hyperendemic 51–75%), with the exception of the holoendemic class (>75%) where the parasite rate was defined in the 1-year age cohort.
The ‘epidemic’ class is restricted to the temperate regions in these maps and it should
be noted that this term is used differently today. For a colour version of this figure, the
reader is referred to the online version of this book.

malaria at the peak of its historic distribution (circa 1900) using expert opinion, temperature ranges and rainfall isohyets (Lysenko and Semashko, 1968;
Lysenko and Beljaev, 1969; Kaneko et al., 1998).
Lysenko’s endemicity map was not specific to one human malaria
parasite. The map was created before the advent of geographic information systems (GIS) and lacks geographic precision – as exemplified by a
significant misplacement of the Nile River. Relative to the remote sensing
data available today, the environmental data Lysenko and Semashko used to
refine the endemicity boundaries were both limited and crude. The evidence base used was not described in detail and, since the map was not generated via a formal statistical method, there was no measure of uncertainty
provided. It is therefore difficult to determine how robust the distribution
estimates of Lysenko were.

3. SPATIAL DISTRIBUTION OF P. VIVAX MALARIA,
POPULATIONS AT RISK AND ITS VECTORS
Here, we bring together maps at the regional level (Fig. 1.2) of the
limits of transmission, endemicity and estimates of the populations at risk,
along with the distribution of P. vivax vectors.
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Figure 1.2 Regional tiles of Plasmodium vivax endemic countries. The regional tiles
shown were used to stratify the modelling of P. vivax endemicity. Pink = the Americas;
blue = Africa+; green = Asia; orange = Asia-Pacific; grey = non endemic for P. vivax. For
interpretation of the references to colour in this figure legend, the reader is referred to
the online version of this book.

3.1. P. vivax Malaria Limits and Endemicity
Figure 1.3 shows estimated limits of unstable (light grey) and stable (dark
grey) transmission of P. vivax in Panel 1 (A1–D1) and, within Panel 2 (A2–
D2), levels of endemicity (blue to yellow to red, red being >7% prevalence).
The map is accompanied by two measures of uncertainty in our endemicity estimates: one absolute measure and the second weighted by population
density in each location (Fig. 1.4).
A detailed review of the data and methodology used to create this map
is given at the end of this chapter in Section 6. In brief, we have used 9970
spatiotemporally unique records of parasite prevalence (Fig. 1.3, Panel 1), environmental covariates and a Bayesian geostatistical model with seasonal and agestandardisation components to generate a smooth map of point estimates of
parasite prevalence in all areas with stable transmission (Gething et al., 2012).
Throughout the world, endemicity was predicted within a relatively narrow
range, with the point estimate of the P. vivax PR age-standardised to the 1–99
year age range (PvPR1–99) rarely exceeding 7%. Here, we highlight important
aspects of the methodological approach taken that improve on preceding global
estimates of P. vivax malaria risk, along with key assumptions and constraints:
Temporal influence. The maps presented (Figure 1.3, Panel 2) are of endemicity in 2010 but the data used to inform the model ranged from 1985 to
2010.The model was designed to down-weight older data, so that whilst they
can help inform the contemporary estimates, particularly in areas lacking
contemporary data, these had less influence on our estimates of prevalence.
This was reflected by higher uncertainty those areas reliant on older data.
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Figure 1.3 The spatial distribution of Plasmodium vivax malaria endemicity in 2010
in Asia, Asia-Pacific, the Americas and Africa+. The spatial distribution of P. vivax
malaria endemicity is shown at the regional levels: Asia (A), Asia-Pacific (B), the Americas (C) and Africa+ (D). Panel 1 in A–D shows the 2010 spatial limits of P. vivax malaria
risk defined by Plasmodium vivax annual parasite incidence (PvAPI) with further medical intelligence, temperature and aridity masks. Areas were defined as stable (dark grey
areas, where PvAPI ≥ 0.1 per 1000 per annum), unstable (medium grey areas, where
PvAPI < 0.1 per 1000 p.a.) or no risk (light grey, where PvAPI = 0 per 1000 p.a.). Only the
P. vivax malaria endemic countries (PvMECs) in each region are shaded in. The community surveys of P. vivax prevalence conducted between January 1985 and June 2010 are
plotted. The survey data are presented as a continuum of light blue to red (see map legend), with zero-valued surveys shown in white. Panel 2 in each region shows the modelbased geostatistics (MBG) point estimates of the annual mean PvPR1–99 for 2010 within
the spatial limits of stable P. vivax malaria transmission, displayed on the same colour
scale. Areas within the stable limits (Panel 1) that were predicted with high certainty
(>0.9) to have a PvPR1–99 less than 1% were classed as unstable. Areas in which Duffy
negativity gene frequency is predicted to exceed 90% (Howes et al., 2011) are shown
in hatching for additional context. For interpretation of the references to colour in this
figure legend, the reader is referred to the online version of this book.
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Figure 1.3, cont’d

Seasonal fluctuations.The estimates provide the average P. vivax endemicity
over a year. Seasonal fluctuations of parasite prevalence were included in
the model structure but aggregated in the outputs. Seasonal estimates are
not currently available and would be confounded by relapses that can occur
outside the transmission season (see the section ‘Relapse of P
 lasmodium
vivax blood infections’ below).
Smoothness of the global map. Malaria endemicity can be highly heterogeneous over small distances and, therefore, our model produced candidate
maps that are also highly heterogeneous. An artefact of presenting one map
that summarises the full model output using either a mean or a median
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Figure 1.3, cont’d

of the estimates for each location was that this process smoothed out the
patchy nature of malaria endemicity.
Use of parasite prevalence data. It is important that our estimates were based
on real data, with a mathematical model that compensated for the fact that
the real data were neither comprehensive nor universally contemporary.
The most commonly available metric from almost all countries is prevalence (often referred to as parasite rate (PR)), estimated from surveys that
are conducted using a common methodology (Hay et al., 2008). Prevalence
data are relatively robust but have the disadvantage that required sample
sizes become prohibitively large when prevalence rates are low.
Use of clinical incidence data. Annual clinical incidence per 1000 people
(commonly referred to as annual parasite incidence (API) data) from public
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Figure 1.3, cont’d

health records is more sensitive at low parasite prevalence values, but is
biased. For example, we do not know the proportion of people within every
district who do not seek care for malaria at a public health facility and are
therefore missed by the statistics. We used clinical incidence data to define
the areas where we know very little, other than that malaria exists but is
so low as to be essentially unquantifiable using available data. We referred
to this level of risk as unstable malaria transmission and defined it as less
than one case per 10,000 people per year (or <0.1 API). At very low levels of incidence, a small change is proportionally large so API is measured
across an administrative (ADMIN) division and we averaged this figure over
4 years (providing data are available).

12

Katherine E. Battle et al.

Figure 1.3, cont’d

Use of biological data to refine the limits defined by clinical incidence data.
Remote sensing surfaces, showing temperature (Fig. 1.5) and aridity
(Fig. 1.6), and biological models were used to identify areas where extreme
temperature or aridity regimes would reduce or preclude P. vivax transmission. The limits of transmission are adjusted accordingly.
The effect of interventions. The PR data used came from many areas where
interventions (ITNs, indoor residual spraying (IRS), etc.) have been implemented so that the effect of these interventions at these locations was
included within the estimates produced by the model. This effect was not
modelled separately and cannot be extracted from our results.
The impact of Duffy negativity. Since Duffy negative individuals are largely
refractory to P. vivax infection (Miller et al., 1976), high population frequencies of this phenotype suppress endemicity, even where conditions are
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Figure 1.3, cont’d

otherwise well suited for transmission (Guerra et al., 2010). We incorporated recent global estimates of the frequencies of Duffy negativity (Howes
et al., 2011) in our model. Regional maps of the predicted prevalence of
Duffy negativity are shown in Fig. 1.7. The fraction of the population at
each population that was Duffy-negative was excluded from the denominator in the prevalence data, such that any P. vivax-positive individuals are
assumed to have arisen from the Duffy-positive population subset. Thus, in
a location with 90% Duffy negativity, five positive individuals in a survey
of 100 would give an assumed prevalence of 50% amongst Duffy positives. Correspondingly, prediction of prevalence was then restricted to the
Duffy-positive proportion, with the final prevalence estimate re-converted
to refer to the total population.This approach meant prevalence could never
exceed the Duffy-positive proportion of a population and, where P. vivax
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Figure 1.4 Uncertainty associated with predictions of Plasmodium vivax endemicity
in Asia, Asia-Pacific, the Americas and Africa+.
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Figure 1.4, cont’d
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Figure 1.4, cont’d The uncertainty associated with P. vivax malaria endemicity predictions is shown at the regional levels: Asia (A), Asia-Pacific (B), the Americas (C) and
Africa+ (D). Panel 1 in A–D shows the ratio of the posterior inter-quartile range to the
posterior mean prediction at each pixel. Large values indicate greater uncertainty: the
model predicts a relatively wide range of PvPR1–99 as being equally plausible given the
surrounding data. Conversely, smaller values indicate a tighter range of values have
been predicted and, thus, a higher degree of certainty in the prediction. Panel 2 in each
region shows the same index multiplied by the underlying population density and rescaled to 0–1 to correspond to Panel 1. Higher values indicate areas with high uncertainty
and large populations. Areas of no risk within PvMECs are shown in grey and countries
not endemic for P. vivax or outside the named region are in white. For a colour version of
this figure, the reader is referred to the online version of this book.

survey data were sparse across much of Africa, the prevalence predictions
could borrow strength from the Duffy negativity map because predictions
of prevalence were restricted to a narrower range of possible values.
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Figure 1.4, cont’d

Transmission in Africa. The predominance of Duffy negativity in Africa
has led to a historical perception that P. vivax is absent from much of the
continent (Rosenberg, 2007). Evidence exists, however, of autochthonous
P. vivax transmission in nearly every African country (Guerra et al., 2010)
and that P. vivax is capable of causing severe disease in the continent (Mahgoub et al., 2012). Therefore, we did not preclude any areas at risk before
modelling endemicity. We initially assumed stable P. vivax transmission,
unless the biological mask layers or clinical incidence (API) data confirmed
otherwise. In some regions provisionally labelled as stable in this way, the
endemicity model subsequently predicted extremely low prevalence, either
because of survey data reporting zero infections or because of very high
Duffy-negativity prevalence. Locations predicted with high certainty (probability >0.9) of being less than 1% prevalence were therefore re-assigned
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Figure 1.4, cont’d

to the unstable transmission class. This re-assignment is shown in the final
limits presented in Fig. 1.3A1–D2.
Relapse of Plasmodium vivax blood infections. The prevalence surveys
used detect parasites in the blood and not latent infections in the liver. Primary blood infections detected by these surveys are indistinguishable from
relapses caused by previously dormant parasites from the liver.The estimates
produced by the model were, therefore, the combined prevalence of primary infections and relapses.
The impact of low parasitaemia levels. Plasmodium vivax parasites are typically found in the blood at much lower densities than are found for
P. falciparum and so are less likely to be detected by some diagnostic methods. We made no direct adjustments for these ‘sub-patent’ infections. It
is important to note that P. vivax can cause fever and anaemia at lower
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Figure 1.5 Environmental suitability for transmission of P. vivax as defined by temperature in Asia, Asia-Pacific, the Americas and Africa+. Areas shaded green in Asia
(A), Asia-Pacific (B), the Americas (C) and Africa+ (D) are those in which no windows
exist across an average year in which the annual temperature regime is likely to support
the presence of infectious vectors. The temperature suitability model is described in full
elsewhere (Gething et al., 2011b). For interpretation of the references to colour in this
figure legend, the reader is referred to the online version of this book.

parasitaemia levels than P. falciparum (Mendis et al., 2001; Mueller et al.,
2009a).
Uncertainty in the estimates of endemicity. The modelling framework
allowed the uncertainty in predicted endemicity values to vary between
locations, depending on the observed variation, density and sample size
of surveys and the predictive utility of the suite of environmental covariates (described in detail in Section 1.6). The uncertainty associated with
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Figure 1.5, cont’d

predictions is summarised by maps showing the ratio of the inter-quartile
range (IQR) to its mean (Fig. 1.4A1–D1). The IQR is a simple measure of
the precision with which each value is predicted, and standardisation by the
mean produces an uncertainty index less affected by underlying prevalence
levels and more illustrative of relative model performance. This index was
then also weighted by the underlying population density to produce a second map indicative of those areas, where uncertainty is likely to be most
operationally important (Fig. 1.4A2–D2).

3.2. Population at Risk of P. vivax Malaria
Table 1.1 shows our estimates of the population at risk (PAR) of infection and a detailed description of the methodology used to generate these
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Figure 1.5, cont’d

estimates is given at the end of this chapter in Section 6. In brief, these
estimates were generated by combining maps of the limits of transmission
described above with 1 × 1 km resolution gridded population surfaces for
2010 projected from the Global Rural-Urban Mapping Project (GRUMP)
year 2000 beta version population counts (Balk et al., 2006; CIESIN/
IFPRI/WB/CIAT, 2007). Regional maps of 1 × 1 km gridded population
estimates for 2010 are shown in Fig. 1.8. Fine-scale population data were
used to ensure the detailed variations in risk level described in our limits
maps are appropriately assigned to the underlying population.

3.3. Vectors of the P. vivax Parasite
Figure 1.9 shows the distribution of Anopheles species considered to be
the dominant vector species/species complexes (DVS) of human malaria
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Figure 1.6 Environmental suitability for transmission of P. vivax as defined by
extreme aridity in Asia, Asia-Pacific, the Americas and Africa+. Areas shaded in brown
are those classified as bare areas by the GlobCover land cover product in Asia (A), AsiaPacific (B), the Americas (C) and Africa+ (D), interpreted as lacking sufficient moisture to
support populations of Anopheles necessary for transmission. For interpretation of the
references to colour in this figure legend, the reader is referred to the online version of
this book.

(P. falciparum and P. vivax) within each region of the world (Sinka et al.,
2012), and a detailed description of the methods to generate these maps
is given in Section 6.4. In brief, the distribution of each of the dominant
species or species complex was individually predicted using occurrence
data (mainly abstracted from published surveys), the Boosted Regression
Trees (BRT) ecological niche modelling technique (Elith et al., 2008), environmental covariates, and species range expert opinion maps derived from
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Figure 1.6, cont’d

consultation with vector experts (Hay et al., 2010c; Sinka et al., 2010a,
2010b, 2011). The resulting maps illustrate the predicted distribution of the
DVS using a probability of occurrence metric. While the ecological covariates of the model are based on annualised means of temperature and precipitation, the maps cannot represent the season fluctuations that may occur in
the distribution of the DVS, which may be significant in those that extend
into temperate climes. Expert opinion was also used to classify the most
important species /combinations of species per region (i.e. those with the
highest impact) and their individual distributions were overlaid, with the
most competent vectors species uppermost, to generate the maps shown.
The combined vector map aims to aid vector control planning by showing
which species need to be controlled in each area.
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Figure 1.6, cont’d

A species complex is a group of closely related species that are often
indistinguishable based on morphology alone. Reference to a complex may
be indicated by referring to the species as ‘sensu lato’ or ‘s.l.’ (e.g. Anopheles
gambiae s.l.) meaning ‘in the broad sense’, whereas ‘sensu stricto’ or ‘s.s.’ (‘in
the strict sense’) indicates the species alone (often a sibling within a species
complex has the same name as the complex). The presence of species complexes adds a level of complexity to vector control efforts. Sibling species
that are morphologically indistinguishable and often sympatric within an
area can have such varied bionomics that one sibling is rendered a dominant
vector and the other a non-vector (Meek, 1995; Manguin et al., 2008). The
proper identification of species and knowledge of their ranges, often rapidly
altered by expanding agriculture and land use changes (Amerasinghe et al.,
1991a; Amerasinghe and Indrajith, 1994; Lee, 1998; Singh and Mishra, 2000;
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Figure 1.7 Distribution of the Duffy negative phenotype in Asia, Asia-Pacific, the
Americas and Africa+. The prevalence of the Duffy-negative phenotype, Fy(a−b−), is
shown in Asia (A), Asia-Pacific (B), the Americas (C) and Africa+ (D). The Duffy prevalence
model is full described elsewhere (Howes et al., 2011). Only the PvMECs in each region
are shown in colour. For a colour version of this figure, the reader is referred to the online
version of this book.

Vythilingam et al., 2005), is vital for appropriate allocation of vector control
resources.
A search of the current literature has identified 71 species/species complexes with the potential ability to transmit P. vivax (Table 1.2), which
includes all 41 species classified by Sinka et al. (2010a, 2010b, 2011) as DVS,
34 of which are shown in Fig. 1.9 (a number of species were not included in
the global multi-species maps as they were of lesser importance when classified by region and were completely overlaid by higher impacting vectors).
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Figure 1.7, cont’d

This suggests, and the literature appears to corroborate, that all vectors
capable of transmitting P. falciparum are also capable of transmitting P. vivax.
Interestingly, the reverse (all P. vivax vectors being capable of transmitting P.
falciparum) appears not to hold true.

4. REGIONAL SUMMARIES OF THE PUBLIC HEALTH
SIGNIFICANCE OF P. VIVAX MALARIA
4.1. Asia
The Asia region (defined for these purposes as mainland Asia but excluding the Malaysian Peninsula; Fig. 1.2) has, amongst the highest endemicity estimates of P. vivax malaria globally (Fig. 1.3A2), a diverse range of
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Table 1.1 Area and Populations at Risk of Plasmodium vivax Malaria in 2010
Area (million km2)
Population (million)
Region

America
Africa+
Asia
AsiaPacific
World

Unstable

Stable

Any risk

Unstable

Stable

Any risk

1.38
20.60
5.60
0.96

8.08
1.86
3.63
1.78

9.46
22.46
9.24
2.74

87.66
48.72
1236.92
150.17

49.79
37.66
812.55
64.90

137.45
86.38
2049.47
215.07

28.55

15.34

43.90

1523.47

964.90

2488.37

Risk is stratified into unstable risk (PvAPI < 0.1 per 1000 people p.a.) and stable risk (PvAPI ≥ 0.1 per
1000 people p.a.). America = Central and South America; Africa+ = Africa,Yemen and Saudi Arabia;
Asia = mainland Asia excluding the Malaysian Peninsula; Asia-Pacific = southern islands of Asia-Pacific
and the Malaysian Peninsula.
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Figure 1.8 Population surfaces for 2010 in Asia, Asia-Pacific, the Americas and
Africa+. Population estimates in Asia (A), Asia-Pacific (B), the Americas (C) and Africa+
(D) were estimated from the GRUMP beta 2000 data (Balk et al., 2006; CIESIN/IFPRI/WB/
CIAT, 2007) and are shown here at 0.0083 × 0.0083 decimal degree resolution (0.0083
decimal degrees is approximately equal to 1 km at the equator). Only the PvMECs in
each region are shown in colour. For a colour version of this figure, the reader is referred
to the online version of this book.

epidemiologically important vectors, and by far the largest populations at
risk. A low prevalence of Duffy negativity and high population densities in
many of the endemic countries in Asia make it an important global P. vivax
transmission setting to understand and the vast majority (84%) of the global
PAR of stable P. vivax transmission live in this region.
Defining the limits of transmission. API data were available for all countries except Uzbekistan and Democratic People’s Republic of Korea (Korea
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Figure 1.8, cont’d

DPR). Five countries reported data up to the year 2010 (Bhutan, Georgia,
Nepal, Sri Lanka and Thailand) with the majority (14/23) providing data up
to 2008. India and China’s last year of reporting was 2007.
Transmission was estimated to span 9 million square kilometres of land
in Asia (around 45% of the total land area in Asia). The majority of this area
(61%; 5.60 million km2) was at unstable risk. The areas at risk in India and
China covered 2.97 and 2.82 million km2 each and, therefore, comprised
63% of the total area at risk in Asia (Panel A1 of Fig. 1.3).
Estimating endemicity. There were 2665 records of prevalence data collected from the region. The three most data-rich countries were Viet Nam
(n = 657), Afghanistan (n = 493) and Bangladesh (n = 365), as illustrated in
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Figure 1.8, cont’d

Panel A1 of Fig. 1.3.The predicted prevalence estimates in stable transmission
areas in Asia were highly heterogeneous. Areas with point estimates above
7% were found in small parts of India, Myanmar and Thailand. Regions
with PvPR1–99 estimates between 3.5 and 7% were found in large areas of
India and pockets of China, Myanmar,Thailand, Cambodia and Lao People’s
Democratic Republic (Lao PDR). Uncertainty maps reveal that areas of
high uncertainty correspond with high transmission areas. These areas also
had sparse prevalence survey data. Relative to its size, India had very little
prevalence data available. Myanmar and Thailand also had large regions with
stable transmission but with few surveys to support the prevalence estimates.
While predictions on the Korean peninsula were made with relatively high
certainty (Fig. 1.4A1), there were no survey data available from Korea DPR.
Known prevalence values from this region as well as from India, Myanmar,
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Figure 1.9 Distribution of dominant vector species globally and in Asia, Asia-Pacific,
the Americas and Africa+.
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Figure 1.9, cont’d The global distribution of the main dominant vector species is shown
in Panel A alongside the predicted endemicity of P. vivax in 2010. The distribution of
the primary vector species are also shown at the regional level: Asia (B), Asia-Pacific (C),
the Americas (D) and Africa+ (non-endemic countries are shaded white). The legend for
Africa+ is disaggregated in to Africa and the Middle east because only the primary vector species in Africa are shown in the map. For colour version of this figure, the reader is
referred to the online version of this book.

Thailand and parts of China with stable vivax transmission would improve
the certainty of PvPR1–99 predictions for the area as a whole. Regions with
low endemicity and high density of surveys, such as Afghanistan, Cambodia
and the small region with stable transmission in Turkey, were predicted with
high certainty. The population-weighted uncertainty map differs substantially for parts of this region (Fig. 1.4A2). Incorporating population estimates allows weighting to highlight areas where high uncertainty and large
populations coincide. Thus, sparsely populated areas of Myanmar, Thailand,
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Cambodia, Lao PDR, Viet Nam and Korea DPR displayed small values of
this index despite uncertain predictions of prevalence. Conversely, values for
highly populated areas across India, parts of Pakistan and the stable transmission region in China, were inflated substantially. Predictions in this region
would be best improved, therefore, with more detailed prevalence data from
these population centres.
Population at risk. The PAR in Asia was, by far, the largest of all of the
regions due to large areas of risk and high population densities. There
were over two billion people living at risk in this region in 2010, which
constituted 82% of the total global PAR. The greatest PAR was found in
India, China and Pakistan with 1.13 billion, 462 and 169 million at risk,
respectively. India’s PAR comprised more than half (55%) of the Asiaregion PAR. Together, China and Pakistan made up another 30% (23 and
8%, respectively), indicating that 85% of the region’s PAR was attributable to three nations. These nations also had the largest populations in this
region. Compared to India and Pakistan, a smaller proportion of China’s
overall population was living at risk of P. vivax. Of China’s estimated 1.4
billion people, 33% were at risk of P. vivax, whereas 95% of India’s 1.2 billion and 90% of Pakistan’s 188 million people were living at some level of
risk. When we consider both levels of risk (unstable and stable transmission), we find that 60%, or 1.2 billion, of the PAR in Asia experienced
unstable risk, indicating that over 800 million individuals in this region
lived in stable transmission areas. Countries devoid of stable transmission
areas were Iraq, Kyrgyzstan and Uzbekistan. Countries with the greatest
population at stable risk in this region were again India (642.07 million),
Pakistan (43.82 million) and China (31.92 million). Other countries that
had large (>10 million) PAR living in stable transmission areas were Korea
DPR (21.07 million), Myanmar (20.48 million), Thailand (17.11 million)
and Bangladesh (16.04 million). Ninety eight percent of the population
living in stable transmission areas was, therefore, found in 30% (7 out of
24) of the countries in Asia.
Vectors. Of the 35 potential P. vivax vector species found within Asia as
a whole (Table 1.2), there are 19 DVS (Sinka et al., 2011) of which, at least
seven are considered to be species complexes (Harbach, 2004). Nine DVS
are found solely in the Asia region, whilst the remaining 10 have distributions extending into the Asia-Pacific region.
A total of 10,667 unique occurrence points were georeferenced for the
19 DVS across Asia. Records of species occurrence obtained from observations recorded to point (≤10 km2) and wide area (10–25 km2) locations
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(sites) were used for analyses. In some cases, more than one occurrence
point was obtained for a single site. The greatest number of points were
found for the Anopheles culicifacies complex (n = 1568) followed by the
Anopheles subpictus (n = 1143) and Anopheles barbirostris (n = 1064) complexes. From the 15 Asian P. vivax malaria endemic countries (PvMECs),
where anopheline occurrence data were found, data were obtained from
5388 sites. The greatest number of sites were in Myanmar (n = 1830), India
(n = 1529) and China (n = 355). There was only one reported occurrence
located in Turkey.
The predicted distributions of the DVS in Asia resulted in a complex
multi-species map, where the main vector species overlap over large areas of
land and exist independently in small areas (Fig. 1.9B). It is beyond the scope
of this review to describe the individual distributions and bionomics of the
19 potential DVS in this region, however, a complete discussion of the ranges
and bionomics of the global DVS may be found elsewhere (Sinka et al.,
2010a, 2010b, 2011, 2012). The DVS described in the following paragraphs
are those that were deemed to be primary malaria vectors by the project’s
technical advisory group (TAG), which are therefore shown prominently in
Fig. 1.9A, and showed conclusive evidence for the ability to transmit P. vivax
(Table 1.2). The potential primary DVS that met these criteria were the
An. culicifacies complex (Culicifacies Complex; An. culicifacies s.l.), the Anopheles dirus complex (Dirus Complex; An. dirus s.l.), the Anopheles minimus
complex (Minimus Complex; An. minimus s.l.), Anopheles sinensis, Anopheles
stephensi and Anopheles superpictus.
Anopheles culicifacies s.l. is a prominent vector across the Indian subcontinent, found in sympatry with An. stephensi and Anopheles fluviatilis s.l.
Species B of the Culicifacies Complex is considered a non-vector of P. falciparum, currently attributed to highly zoophilic behaviour. However, there
is evidence shown in Table 1.2 that the species is also partially refractory to
P. vivax and, hence, perhaps to malaria parasites overall (Adak et al., 2005;
Vijay et al., 2011). Evidence of wild-infected populations and experimental
infections suggest that at least species A and C of the complex are primary
vectors of malaria on the Indian subcontinent. Bangladesh, Myanmar, Thailand, Cambodia, Lao PDR and Viet Nam are dominated by the Dirus and
Minimus Complexes (Fig. 1.9B). The range of the An. sinensis complex
covers the majority of China, where it is shown to co-exist with Anopheles lesteri along the eastern areas of the country and the Korean peninsula.
However, the overlapping distributions of these two vector species may be
an artefact of mis-identification in some areas rather than true sympatry
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Table 1.2 Known and potential vector species of Plasmodium vivax
P. vivax
Distribution
vector
Species, species
and bionomics
complex* or group reviewed by MAP† (Yes/No)‡ Notes and reference(s)
Asia

An. atroparvus van
Thiel

Yes

An. baimaii Sallum Yes (part of the
An. dirus com& Peyton
plex)
Yes
An. culicifacies
complex

Yes

Yes(?)
Yes

Yes(?)

An. atroparvus has been shown to be experimentally infected with P. vivax by
humans (Daskova and Rasnicyn, 1982) and (Collins et al., 1980; Collins et al.,
2009).This species has been shown to be refractory to P. falciparum infection (de
Zulueta et al., 1975; Daskova and Rasnicyn, 1982; Romi et al., 2001).
P. vivax and P. falciparum are commonly found in An. baimaii (Sallum et al.,
2005; Obsomer et al., 2007), but original sources do not differentiate the
members of the Dirus Complex (Prakash et al., 2001).
Naturally P. vivax-infected An. culicifacies were found in Madhya Pradesh (Species C and D) (Subbarao et al., 1992) and Uttar Pradesh (Species A) (Subbarao et al., 1988) in India, and in Sri Lanka (Amerasinghe et al., 1991b).
An. culicifacies have been experimentally infected with P. vivax in from
infected monkeys (Collins et al., 2009) and laboratory colonies established
from wild caught An. culicifacies (Species A, B and C) were infected with
vivax from blood drawn from infected humans (Adak et al., 1999). Species
A and C showed relatively high oocyst infections but Species B did not.
Sporozoite infections were relatively high in Species A compared to Species C and negligible in Species B. There is evidence that Species B may be
refractory to P. vivax infection (Adak et al., 2006;Vijay et al., 2011).
Sporozoites were detected in specimens collected in Iran and the species is said
to transmit both P. vivax and P. falciparum (Eshghi et al., 1976). Both oocytes
and sporozoites were found in an An. fluviatilis (Species T) laboratory colony
infected by human volunteers under controlled conditions (Adak et al., 2005).
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An. fluviatilis
complex

Yes(?)

No

Yes

An. messeae
Falleroni

Yes

Yes(?)

An. nimpe Nguyen, No (part of the
Hyracanus
Tran & Harbach
Group)
An. philippinensis- No
nivipes complex
No
An. pulcherrimus
Theobald

Yes(?)
Yes
Yes

Yes

An. sawadwongporni No (part of the
Maculatus
Rattanarithikul
Group)
& Green
Yes
An. sergentii
(Theobald)

Yes
Yes

P. vivax circumsporozoite proteins were detected in An. sergentii specimens
sampled from desert oases in Egypt (Kenawy et al., 1990).
Continued
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An. sacharovi Favre Yes (part of the
Maculipennis
Subgroup)

Wild P. vivax-infected Hyracanus Group mosquitoes were found in Assam,
India (Rattanarithikul et al., 1996; Prakash et al., 2004).
An. messeae was implicated as a vector of P. vivax in eighteenth and nineteenth
century Finland (Hulden et al., 2008; Hulden, 2009) and the authors refer
to evidence of An. messeae as a vector in Russia (Sokolova and Snow, 2002),
but only indirect evidence linking malaria incidence with vector density
was provided.
An. nimpe was implicated as a vector (Nguyen et al., 2000) of P. vivax and
P. falciparum after being sampled in coastal Viet Nam, but direct evidence
of infection was not available.
Wild-infected An. philippinensis-nivipes s.l. specimens were found to be positive for P. vivax in Assam, India (Prakash et al., 2004).
An. pulcherrimus is thought to be the main vector in Afghanistan (Brooker
et al., 2006). Plasmodium vivax (VK210 and VK247 subtypes) was detected
in specimens collected in Afghanistan (Rowland et al., 2002) and P. vivax
circumsporozoite proteins were detected though enzyme-linked immunosorbent assay (ELISA) in wild-infected wild-infected mosquitoes (the vast
majority of which were An. pulcherrimus), but the authors do not explicitly
state that P. vivax was found in An. pulcherrimus (Faulde et al., 2007).
P. vivax circumsporozoite antigens were detected in wild populations sampled
in Turkey (Simsek et al., 2010). P. vivax oocysts and sporozoites were
detected in the salivary glands of a laboratory colony of An. sacharovi fed on
vivax infected humans (Kasap, 1990).
P. vivax (VK247) was detected in specimens collected in Thailand (Coleman
et al., 2002).
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Hyracanus Group

An. stephensi
Liston

Yes

Yes

An. superpictus
Grassi

Yes

Yes

An. varuna Iyengar No (part of the
Aconitus Subgroup)

Yes
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Table 1.2 Known and potential vector species of Plasmodium vivax—cont’d
Species, species
Distribution
P. vivax
complex* or
and bionomics
vector
group
reviewed by MAP† (Yes/No)‡ Notes and reference(s)

P. vivax (VK210 and VK247) was detected in specimens collected in Afghanistan (Rowland et al., 2002). An. stephensi has been experimentally infected
with P. vivax from infected monkeys (Basseri et al., 2008; Collins et al.,
2009) and humans (Adak et al., 2005); both oocysts and sporozoites found
were found in the mosquitoes.
P. vivax (VK247) was detected in specimens collected in Afghanistan (Rowland et al., 2002). Laboratory colonies An. superpictus have been infected
with P. vivax-infected humans; oocysts and sporozoites were in salivary
glands (Kasap, 1990). This species seems to be generally implicated as a
vivax vector in other articles.
Wild-infected mosquitoes were found to be positive for P. vivax in Assam,
India (Prakash et al., 2004).

Asia and Asia-Pacific

Yes

An. annularis van
der Wulp
An. barbirostris
complex

Yes

Yes

Yes

Yes

P. vivax sporozoites have been detected (by ELISA) in wild captured An. aconitus in Sri Lanka (Amerasinghe et al., 1991b). Laboratory studies revealed
that An. aconitus forms B and C were susceptible to P. vivax and P. falciparum,
and that An. aconitus form C was susceptible only to P. vivax (Junkum et al.,
2005).
P. vivax sporozoites have been detected (by ELISA) in wild captured An. annularis in Sri Lanka (Amerasinghe et al., 1991b) and India (Prakash et al., 2004).
P. vivax circumsporozoite proteins were found in specimens collected in Thailand with infectivity rates of 0.24% (Rattanarithikul et al., 1996) and 4.8%
(Frances et al., 1996).
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An. aconitus Dönitz Yes

Yes

An. dirus complex

Yes

Yes

An. donaldi Reid

No

Yes

An. hodgkini Reid

No

Yes

An. karwari (James) No

Yes

An. kochi Dönitz

Yes

No

Yes
An. lesteri Baisas
& Hu (synony
mous with
An. anthropophagus
Xu & Feng)

Yes(?)

An. letifer
Sandosham

Yes(?)

No

P. vivax (VK210) was detected in specimens collected in Thailand (Coleman
et al., 2002).
P. vivax circumsporozoite proteins have been detected in an An. dirus specimen
collected in Thailand (Baker et al., 1987). The vectorial capacity of An. dirus
for P. vivax has been estimated (Prakash et al., 2001). Experimental infection
from humans (Wirtz et al., 1985), monkeys (Collins et al., 2009) and membrane feeding has been shown (Coleman et al., 2004; Junkum et al., 2005).
P. vivax circumsporozoite proteins have been detected in An. donaldi specimens sampled in Malaysia (Seng et al., 1999). An. donaldi was successfully infected with P. vivax and P. falciparum sporozoites in the lab and was
capable of transmitting both species to man (Hardin et al., 1973; Harrison
and Scanlon, 1975).
P. vivax was detected in specimens collected in Thailand (VK247) (Coleman
et al., 2002).
P. vivax circumsporozoite proteins in An. karwari specimens collected in
Thailand (Frances et al., 1996).
Wild P. vivax-infected An. kochi mosquitoes were found in Assam, India
(Prakash et al., 2004).
An. lesteri (An. anthropophagus) were experimentally infected with P. vivax from
humans in Republic of Korea (Shin et al., 2002). Human laboratory feedings showed An. lesteri to be a highly competent vector (Joshi et al., 2009).
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Specimens collected in Sarawak, Malaysia were found to be sporozoite positive and although the species of the parasite was not identified, >90% of
the malaria infections in the region at the time were due to P. vivax (Chang
et al., 1997). Implied transmission, but with no direct evidence, is described
in other references (Rahman et al., 1997; Fryauff et al., 1998).
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An. campestris Reid No

Yes (sister species
in the Leucosphyrus Complex)
No

Yes

An. minimus
complex

Yes

Yes

An. nigerrimus
Giles

No

Yes

An. sinensis
Wiedemann

Yes (part of the
Hyracanus
Group)
Yes

Yes

Yes

Yes(?)

An. subpictus
complex
An. sundaicus
complex

?

Yes

P. vivax circumsporozoite proteins have been detected in An. leucosphyrus
specimens sampled in Malaysia (Seng et al., 1999). However, the species
sampled was most likely An. latens, which was commonly misidentified as
its sister species An. leucosphyrus (Sallum et al., 2005).
No references were found to confirm that An. ludlowae transmits P. vivax, but
it is a potential vector in areas where vivax malaria is found (e.g. the Philippines and Indonesia) (Lien et al., 1977; Wooster and Rivera, 1985).
P. vivax was detected in specimens collected in Thailand (VK210 and VK247)
(Coleman et al., 2002) and India (VK247) (Prakash et al., 2004).
An. minimus has also been experimentally infected with P. vivax from
monkeys (Rattanarithikul et al., 1996; Collins et al., 2009).
P. vivax (VK210) circumsporozoite proteins have been detected in
An. nigerrimus sampled in China (Alam et al., 2010) and An. nigerrimus has
been incriminated as a vector there (WHO, 1986).
P. vivax (VK210 and VK247) was detected in specimens collected in the
Republic of Korea (Lee et al., 2002). Deliberate infection was also observed
in laboratory conditions (Shin et al., 2002).
P. vivax circumsporozoite proteins have been detected in An. subpictus sampled
in Sri Lanka (Amerasinghe et al., 1991a).
An. sundaicus is described as a vector of primarily P. falciparum malaria,
implying that it will also transmit P. vivax (Am et al., 1993) and P. vivax
oocysts and sporozoites have been found in infected laboratory colonies
(Adak et al., 2005).
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An. leucosphyrus
Dönitz & An.
latens Sallum &
Peyton
An. ludlowae
(Theobald)
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Table 1.2 Known and potential vector species of Plasmodium vivax—cont’d
Species, species
Distribution
P. vivax
complex* or
and bionomics
vector
group
reviewed by MAP† (Yes/No)‡ Notes and reference(s)

No

Yes

No

Yes

P. vivax circumsporozoite proteins were detected in An. tessellatus species
sampled in Sri Lanka (Amerasinghe et al., 1991a).
P. vivax sporozoites have been detected (by ELISA) in wild captured An. aconitus in Sri Lanka (Amerasinghe et al., 1991a) and India (Prakash et al., 2004).

Asia-Pacific

An. balabacensis
Baisas

Yes (part of the
Yes(?)
An. leucosphyrus
complex)

An. farauti complex
An. flavirostris
(Ludlow)

Yes

Yes

Yes

?

An. koliensis Owen Yes (part of the
Punctulatus
Group)
Yes
An. maculatus
Theobald/Maculatus Group

Yes

An. punctulatus
complex

Yes

Yes

Yes

Sporozoites were found in specimens collected in Central Java, Indonesia
(Barcus et al., 2002) and Palawan, Philippines (Schultz, 1992). Laboratory
reports indicate transmission of P. vivax to non-human primates (Collins
et al., 1980).
P. vivax circumsporozoite proteins were found in specimens collected in
Papua New Guinea (Burkot et al., 1988).
An. flavirostris has been described as the ‘principal vector’ in the Philippines, where P. vivax and P. falciparum malaria occur (Foley et al., 2003)
and has been found with sporozoites in Malaysia (Hii et al., 1985) and the
Philippines (Oberst et al., 1988), but the parasite species was not
given.
P. vivax circumsporozoite positivity of 0.76% was reported for wild-infected
An. koliensis in Papua New Guinea (Attenborough et al., 1997).
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An. tessellatus
Theobald
An. vagus Dönitz

P. vivax (VK210 and VK247) was detected in An. maculatus specimens collected
in Thailand (Coleman et al., 2002). An. maculatus has been experimentally
infected with
P. vivax from monkeys (Wirtz et al., 1985; Collins et al., 2009) with a
reported infectivity of 4.8% (Collins et al., 1980).
P. vivax circumsporozoite antigens were detected in wild populations of the An.
punctulatus complex sampled in Papua New Guinea (Burkot et al., 1988).
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Table 1.2 Known and potential vector species of Plasmodium vivax—cont’d
Species, species
Distribution
P. vivax
complex* or
and bionomics
vector
group
reviewed by MAP† (Yes/No)‡ Notes and reference(s)
The Americas

Yes

Yes

An. albitarsis
complex

Yes

Yes

An. aquasalis
Curry

Yes

Yes

An. argyritarsis
RobineauDesvoidy

No

Yes(?)

P. vivax sporozoites have been detected (by ELISA) in wild captured An.
albimanus in Mexico (Ramsey et al., 1994) and in specimens experimentally infected from humans (Wirtz et al., 1985). Experimental feeding on
monkeys revealed that An. albimanus was much more susceptible to ‘New
World’ P. vivax (P. vivax specimens from Central and South America; 21.2%
infection rate), than ‘Old World’ P. vivax (0.4% infection rate) (Li et al.,
2001). Other laboratory studies using monkeys showed infectivity rates of
only 0.6–0.7% (Collins et al., 1980).
P. vivax infection was detected (by dissection to find presence and ELISA to
determine Plasmodium species) in wild captured An. albitarsis in Northern
Brazil (de Arruda et al., 1986). Mosquito oocyst infection was observed in
laboratory conditions after feeding on infected human volunteers; sporozoites were found in the salivary glands approximately two weeks after
feeding (Klein et al., 1991). P. vivax infection was also seen in mosquitoes
experimentally fed on infected monkeys (Collins et al., 1985).
P. vivax sporozoites have been detected by ELISA in wild captured An. aquasalis
in Brazil (Povoa et al., 2003). An. aquasalis has been experimentally infected
with P. vivax from infected humans (da Silva et al., 2006).
An. argyritarsis naturally infected with P. vivax have been found in Argentina
and the species is identified as a principal vector in parts of Brazil. However, there is some debate whether the species sampled were An. argyritarsis
or misidentified An. darlingi specimens (Linthicum, 1988).
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An. albimanus
Wiedemann

Yes(?)

An. benarrochi
Gabaldón

No

Yes(?)

An. braziliensis
(Chagas)

No

Yes(?)

An. cruzii Dyar &
Knab
An. darlingi Root

No

Yes

Yes

Yes

An. deaneorum
Rosa-Freitas

No (part of
An. albitaris
complex)

Yes

An. freeborni Aitken Yes

Yes(?)
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An. bellator has been found with P. vivax oocysts or both oocysts and sporozoites in Brazil (Deane, 1986) and have been experimentally infected from an
infected human (Rozeboom and Laird, 1942).
Naturally P. vivax infected An. benarrochi were observed in Peru (Flores-
Mendoza et al., 2004), however when mosquito oocyst infection was
observed in laboratory conditions after feeding on infected human volunteers, no sporozoites were found in the salivary glands approximately two
weeks after feeding (Klein et al., 1991).
Naturally P. vivax infected An. braziliensis were observed in Brazil (da SilvaVasconcelos et al., 2002), however when mosquito oocyst infection was
observed in laboratory conditions after feeding on infected human volunteers; no sporozoites were found in the salivary glands approximately two
weeks after feeding (Klein et al., 1991).
P. vivax (VK247) infectivity rates of 0.086–0.179% in wild-infected mosquitoes were reported in Brazil (Branquinho et al., 1997).
An. darlingi specimens were found to be naturally infected with P. vivax in
Amapa (Conn et al., 2002) and Para States (by dissection to find presence
and ELISA to determine Plasmodium species) (de Arruda et al., 1986) in
Brazil and in French Guiana (Girod et al., 2008). Mosquito oocyst infection was observed in laboratory conditions after feeding on infected
human volunteers; sporozoites were found in the salivary glands approximately two weeks after feeding (Klein et al., 1991).
An. deaneorum is a sibling of An. albitarsis complex and may be an important vector in Amazonian Brazil (Conn et al., 2002). This species can be
experimentally infected by both P. vivax and P. falciparum (Klein et al., 1991;
Senise et al., 2006).
An. freeborni has been experimentally infected with P. vivax from humans
(Burgess and Young, 1950) and monkeys (Collins et al., 2009).
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An. bellator Dyar & No
Knab

No

Yes(?)

An. marajoara
Galvão &
Damasceno

Yes (part of the
An. albitarsis
complex)

Yes

An. mediopunctatus
Lutz

No

Yes(?)

An. nuneztovari
complex

Yes

Yes

An. oswaldoi
Peryassú

No

Yes

An. hermsi has been implicated in outbreaks of P. vivax in California (Maldonado et al., 1990; Ginsberg, 1991) and An. hermsi has been experimentally
infected with vivax from monkeys (Collins et al., 2009).
Specimens of An. marajoara (a sibling of An. albitarsis s.l.) collected in Amapa
State, Brazil were found to be naturally infected with vivax and may be
a superior vector for this parasite over An. darlingi in this location (Conn
et al., 2002).
Mosquito oocyst infection was observed in laboratory conditions after
feeding on infected human volunteers and P. vivax sporozoites were
found in the salivary glands approximately two weeks after feeding (Klein
et al., 1991), however other literature states that this species was present in low numbers (de Arruda et al., 1986) or was a non-vector (Vittor
et al., 2006).
P. vivax infection was detected in wild captured An. nuneztovari by dissection
and ELISA was used to determine Plasmodium species in Para State, Northern Brazil (de Arruda et al., 1986).
An. oswaldoi was incriminated as a vector of P. vivax in Southern Colombia
(Quinones et al., 2006) and Northern Brazil (de Arruda et al., 1986).
Mosquito oocyst infection was observed in laboratory conditions after
feeding on infected human volunteers and P. vivax sporozoites were found
in the salivary glands approximately two weeks after feeding (Klein et al.,
1991).
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Table 1.2 Known and potential vector species of Plasmodium vivax—cont’d
Species, species
Distribution
P. vivax
complex* or
and bionomics
vector
group
reviewed by MAP† (Yes/No)‡ Notes and reference(s)

Yes

Yes(?)

An. punctimacula
Dyar & Knab

No

Yes

An. quadrimaculatus Yes
complex

Yes(?)

An. triannulatus
Neiva & Pinto

No

Yes

An. arabiensis
Patton

Yes (part of the
An. gambiae
complex)

Yes

An. funestus Giles

Yes

Yes

An. pseudopunctipennis is implied as the vector of P. vivax in Bolivia (Lardeux
et al., 2007) and has been experimentally infected with P. vivax with variable infectivity rates from different vivax strains (Rodriguez et al., 2000).
While natural infections with P. vivax have been reported from Argentina
and Mexico (Warren et al., 1980), there is also evidence of Plasmodium
sporozoites being absent from An. pseudopunctipennis populations in Belize
(Achee et al., 2000) and El Salvador (Warren et al., 1980) and experiments
have shown An. pseudopunctipennis to be refractory to P. vivax (VK210)
(Gonzalez-Ceron et al., 2007).
Experimental man-to-mosquito transmission has been confirmed, and naturally infected An. punctimacula have been found in Panama (Simmons, 1937;
Quinones et al., 2006; Ulloa et al., 2006; Loaiza et al., 2008).
Species of the An. quadrimaculatus are implied to be vectors of P. vivax malaria
(Jensen et al., 1996) and has been infected in the laboratory from P. vivaxinfected monkeys (Collins et al., 2009).
P. vivax was detected in wild captured An. triannulatus in Para State, Northern
Brazil (de Arruda et al., 1986). Mosquito oocyst infection was observed
in laboratory conditions after feeding on infected human volunteers and
P. vivax sporozoites were found in the salivary glands approximately two
weeks after feeding (Klein et al., 1991).
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P. vivax sporozoites have been detected (by ELISA) in wild captured An. arabiensis in Southern Ethiopia (Taye et al., 2006) and Madagascar (Fontenille
et al., 1990). An. arabiensis have been experimentally infected with P. vivax
from infected monkeys (Collins et al., 2009).
P. vivax (VK247) circumsporozoite proteins were found in An. funestus s.s.
specimens collected in Kenya (Ryan et al., 2006).
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Table 1.2 Known and potential vector species of Plasmodium vivax—cont’d
Species, species
Distribution
P. vivax
complex* or
and bionomics
vector
group
reviewed by MAP† (Yes/No)‡ Notes and reference(s)

An. gambiae Giles/ Yes
An. gambiae
complex

Yes

An. labranchiae
Falleroni

Yes

Yes

An. melas Theobald

?

An. multicolor
Cambouliu

Yes(?)

No

?
?

There is no indication of P. vivax infection, but this may be due to lack of the
parasite within its distribution (Antonio-Nkondjio et al., 2005).
No P. vivax parasites were found in An. multicolor collected in desert oases
in Egypt (El Said et al., 1983; Kenawy et al., 1990; Morsy et al., 1995).
However, the authors infer the potential for transmission and refer to
experimental transmission of P. vivax by An. multicolour under laboratory
conditions.
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Yes (part of the
An. gambiae
complex)
An. merus Dönitz Yes (part of the
An. gambiae
complex)
An. moucheti Evans Yes

P. vivax (VK247) circumsporozoite proteins were found in An. gambiae s.s.
specimens collected in Kenya (Ryan et al., 2006) and An. gambiae has been
infected with P. vivax in laboratory settings from infected monkeys (Wirtz
et al., 1985; Collins et al., 2009).
An. labranchiae has been stated to be a vector of P. vivax (Lindsay and Thomas,
2001; Romi et al., 2001), and a vectorial capacity for P. vivax in An. labranchiae has been estimated (Romi et al., 1997; Romi et al., 2001).
No natural P. vivax infection has been found (Moreno et al., 2004; Bigoga
et al., 2007), but that is perhaps because the indigenous populations, rather
than the mosquito, are refractory to P. vivax (Moreno et al., 2004).
No natural P. vivax infection has been found; An. melas sampled in Tanzania
were found not to be infected with P. vivax (Temu et al., 1998).

Yes

?

An. pharoensis
Theobald

No

Yes

There is no indication of P. vivax infection by ELISA in specimens sampled
in Ethiopia (Nigatu et al., 1994), but this may be due to lack of the parasite
within its distribution (Antonio-Nkondjio et al., 2005).
P. vivax circumsporozoite proteins were detected by ELISA in An. pharoensis
sampled in southwest Ethiopia (Nigatu et al., 1994).

Vector species were identified during the preparation for a series of articles (Hay et al., 2010c; Sinka et al., 2010a, 2010b, 2011, 2012) regarding the dominant vector
species of human malaria. The potential for 71 anopheline species and species complexes to transmit P. vivax are shown alphabetically by region.
*Harbach (2004).
†Sinka et al. (2010a, 2010b, 2011, 2012).
‡Yes = evidence of wild/naturally infected mosquitoes;Yes(?) = evidence of laboratory infected mosquitoes or secondary information implicating species as a vector;
? = no information found to confirm species can carry P. vivax, but nothing to state it cannot, or unconfirmed or unclear references to species P. vivax vector status.
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(Sinka et al., 2012). In addition to its sympatric range with An. culicifacies
s.l. and An. fluviatilis s.l. over India, An. stephensi was predicted to occur in
Afghanistan and Pakistan, where it was sympatric with An. superpictus.
The sources for the following summary can be found in Sinka et al.
(2011) and Sinka et al. (2010a).
The DVS cover a large range of varying ecological niches and the
presence of a large number of species complexes in the region means
that variation in behaviours are often seen. Indeed, behavioural variability
within a species is also common, for example, Anopheles annularis has a range
extending across India, down through South-East Asia, across many of the
Indonesian islands and Timor Island. However, An. annularis only has a focal
role in malaria transmission in selected areas of India. Elsewhere it is considered of little importance.
The Indian DVS have overlapping, sympatric ranges and include a number of species complexes. For example, there are five sibling species in the
An. culicifacies complex (species A, B, C, D and E) and although species A, C,
D and E are all reported to be vectors of malaria in India (Sinka et al., 2011),
species E is the most important because of its highly anthropophilic and
endophilic behaviour. Members of the complex are found across the plains
and up into the highlands (Iyengar, 1954; Barik et al., 2009). Larval habitats
include a variety of man-made and naturally occurring water bodies and
tolerance of brackish water has been observed in species E (Roberts, 1996).
Species C shows plasticity in its behaviour, being found in both forested and
deforested areas. Varied bionomics are therefore observed both within and
among members of this species complex.
The other primary Indian DVS are An. fluviatilis s.l. and An. stephensi.
Variable behaviour is observed amongst the three members of the Fluviatilis Complex (species S, T and U). Within the complex, there are reports
of anthropophilic, zoophilic and exo- and endophagic populations, biting at dusk and during the night. Anopheles stephensi is primarily zoophilic
and endophagic, and both An. fluviatilis s.l. and An. stephensi rest primarily
indoors. Anopheles stephensi is unusual amongst Anopheles species in that it
appears to be able to use virtually any water condition/habitat as a larval
site, hence, its success in urban areas. Less is known regarding the larval
habitats of An. fluviatilis s.l., but the complex is associated with slow-moving
streams or river margins.
Amongst the northern Asia DVS, An. sinensis s.l. and An. superpictus are
considered potential primary vectors of P. vivax. In Thailand, members of the
An. sinensis complex are considered zoophilic and exophagic, and therefore,
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of little vectorial importance. In the Korean Peninsula, on the other hand,
An. sinensis s.l. shows a propensity for biting humans and has been identified as a primary vector (Lee et al., 2001).The larvae of An. sinensis complex
are associated with lowland, shallow, freshwater habitats. Adult females may
hibernate to overwinter from October to April when the temperatures drop
below 19 °C (Chow, 1970). Little is known regarding the biting habits of
An. superpictus, particularly regarding host preference, but they are generally
considered to be exophagic. The larvae are commonly found in shallow,
flowing, fresh, sun-lit water. However, the species can adapt to human influences by using man-made pits and holes.
The primary DVS in the south-eastern part of Asia are the An. dirus and
An. minimus complexes, both of which contain highly competent vector
species. Within the Dirus Complex, which contains seven sibling species,
again there is some variability in behaviours (depending on location and
sibling species) but the main vectors of the complex (An. dirus s.s. and Anopheles baimaii) are both highly anthropophilic and will feed both indoors and
out. Biting activity appears highly sibling/species dependent with Anopheles
scanloni (a focal vector within the complex) biting at dusk, An. dirus biting
in the evening (between 2000 h and 2300 h) and An. baimaii biting as late as
0200 h. In general, outdoor resting both before and after feeding has been
reported for this species complex. The larvae of this complex inhabit small,
temporary, freshwater bodies and are therefore most abundant during the
rainy (monsoon) season. Anopheles minimus s.l. has three siblings, only two
of which (An. minimus s.s. and Anopheles harrisoni) are considered viable
contemporary vectors. Variability in reported behaviour may be a consequence of misidentification or lack of differentiation between these two
species, although both are also considered opportunistic and plastic in their
behaviour. Anopheles minimus s.s. is potentially more anthropophilic, but also
adaptable depending on host availability. Overall, An. harrisoni is considered
more exophagic, exophilic and zoophilic than its sibling. Minimus Complex larvae are typically associated with small- or moderate-sized streams
with slow, clear, cool and partially shaded water. Anopheles minimus s.s. has
been observed in a wider range of habitats from canopied forests to open
fields. Anopheles harrisoni, on the other hand, is more commonly associated
with agricultural areas. Further studies that utilise molecular assays to differentiate sibling species are needed to understand the varied behaviour and
habitat preference of An. minimus s.s. and An. harrisoni.
It is clear that the behaviour of the Asian vectors is complicated, variable
and, as yet, not well understood. However, many of the species do exhibit
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characters that are amenable to control, for example, those that bite indoors
at night are conducive to control using ITNs and indoor resting facilitates
the effectiveness of IRS.
Asia summary. Plasmodium vivax is an important public health problem
across large parts of Asia. Six of the 10 largest PAR estimates of the 95
PvMECs were in Asia and these countries accounted for 87% of the global
PAR. Control of P. vivax in PvMECs in Asia would, therefore, dramatically
reduce the impact of this widespread disease. In Asia, in particular, densely
populated areas are endemic with stable P. vivax transmission. This is due
to environmental suitability as well as a vector species (An. stephensi) that is
well suited to urban transmission.The limits and endemicity maps produced
show that P. vivax has a wide geographic range in this region, across which
the level of transmission is generally low, with small pockets of intense stable
transmission (Fig. 1.3A1 and A2). In high-prevalence areas, such as those
found in parts of India (Orissa State) and Myanmar, the clinical character of
P. vivax has been found to behave more like P. falciparum, resulting in cases of
severe disease and death (Mendis et al., 2001; Baird, 2007; Price et al., 2007a;
Kochar et al., 2009; Mahgoub et al., 2012). Uncertainty estimates were high
throughout India and much of Myanmar and population-weighted estimates emphasise the need to improve the estimates in India with more survey data (Fig. 1.4A1 and A2). Improved P. vivax surveillance in these regions
would greatly improve prevalence predictions. By 2012, several countries in
this region (Azerbaijan, Bhutan, China, Georgia, Korea DPR, Republic of
Korea, Kyrgyzstan, Sri Lanka, Tajikistan, Thailand, Turkey, Uzbekistan and
Viet Nam) had entered the malaria elimination phase (The Global Health
Group and the Malaria Atlas Project, 2011). Improved control in neighbouring countries with intense, stable transmission, such as Myanmar, will
improve the success of those nations already working towards elimination
by reducing the potential for imported malaria from human migration
(Tatem and Smith, 2010). As elimination efforts continue, spatially detailed
mapping will be needed to capture focal areas of transmission that remain.
Further and improved vector surveillance using molecular techniques to
disaggregate species complexes is needed to illuminate which vectors are
truly the primary vector species of P. vivax to allow for appropriate control
measures to be deployed in this highly variable region.

4.2. Asia-Pacific
The Asia-Pacific region (defined for these purposes as the southern islands of
Asia-Pacific and the Malaysian Peninsula; Fig. 1.2) has amongst the highest
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endemicity estimates of P. vivax malaria (Fig. 1.3B) and the most complex
spectrum of vectors. This region has a relatively small land mass, which
means it has a much lower estimated PAR but the range in epidemiological
and entomological factors here mean it presents a unique and challenging
control setting.
Defining the limits of transmission. Annual parasite index data were provided for all the P. vivax-endemic countries in Asia-Pacific. The PvMECs in
this region are Indonesia, Malaysia, the Philippines, Papua New Guinea, the
Solomon Islands, Timor-Leste and Vanuatu.
Transmission was estimated to span 2.74 million km2 of land in this
region, which is primarily made up of islands. The area at risk in AsiaPacific constituted 6% of the global area at risk. Indonesia, the largest country in the region, had the greatest area at risk, consisting of 1.71 million km2
of land, which was 90% of the country’s total area (1.90 million km2) and
60% of the total area at risk for the region.
Estimating endemicity. There were 5277 records of prevalence data collected from Asia-Pacific, which made up more than half (53%) of the global
P. vivax PR survey database.This was primarily due to a large data contribution from Indonesia, which provided 4457 (84%) data points in the AsiaPacific region and 45% of the global dataset (Fig. 1.3B1).
As with mainland Asia, P. vivax endemicity in regions with stable transmission was predicted to vary greatly across the Asia-Pacific region as shown
in Panel B2 of Fig. 1.3. PvPR1–99 point estimates were predicted to exceed
7% in small parts of Indonesia and the Solomon Islands, and much of Papua
New Guinea. Estimates towards the east of the region (Sumatra and Kalimantan) were generally low, while endemicity values of around 5% were
predicted to the north (Malaysian Borneo and the Philippines). The vast
number of surveys from Indonesia meant that the certainty of the predictions in that portion of the region was relatively high (Fig. 1.4B1). Uncertainty was greatest on New Guinea and parts of Borneo, where prevalence
data were sparse. The Philippines, which also had little survey data available,
was predicted with relatively low certainty. Again, the population-weighted
uncertainty map was substantively different (Fig. 1.4B2). While the highly
populated areas of Asia were predicted with less certainty, the high-density
areas of Asia-Pacific, which also had a high number of prevalence surveys
(Indonesia), showed an increase in certainty in the population-weighted
estimates. Uncertainty was also greatly reduced following populationweighting in focal areas in Papua, Indonesia and Papua New Guinea, where
population density is low. The Philippines had relatively low uncertainty
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even when weighted by population estimates, indicating that this region
would benefit from increased prevalence surveillance data.
Population at risk. Relative to the geographic size of the region, AsiaPacific had a large PAR due to pockets of intense transmission in highly
populated endemic areas. It was estimated that there were 215 million people at risk in this region. This was only 11% of the PAR in mainland Asia.
However, the proportion of the population that was at any risk of P. vivax
relative to the total population of the PvMECs in Asia-Pacific was comparable to the Asia region: the PAR was 59% of the total population in AsiaPacific and 58% in Asia. The largest PAR in Asia-Pacific was in Indonesia,
with an estimated population of 129.28 million individuals at risk of P. vivax
out of a total population of 231.60 million (56%) in 2010.The PAR of stable
and unstable transmission in Indonesia was 60% of the PAR of Asia-Pacific
as a whole. The next largest PAR estimates were from the Philippines and
Malaysia. The Philippines had 50.34 million people at risk or 54% of the
total population of the Philippines and 23% of the regional PAR. Malaysia
had 27.88 million (99.8% of the Malaysian population; 13% of the regional
PAR) people at risk. Papua New Guinea had a PAR of 5.64 million (81%
of the national population; 3% of the regional PAR) and Timor-Leste had
1.15 million (98% of the national population; 0.5% of the regional PAR).
The Solomon Islands and Vanuatu had a PAR less than one million: 0.53
and 0.24 million (both nearly 100% of the total national populations and
<0.3% of the regional PAR). Seventy percent of the total PAR in the region
was exposed to unstable transmission. Unstable transmission predominated
in Indonesia and Malaysia, where 79% (26.78 million) and 84% (4.45 million) of the PAR, respectively, were exposed to that level of transmission.
In the Philippines, 53% (26.59 million) of the PAR lived in areas of stable
transmission. Nearly all of the transmission in Vanuatu was stable (99.57%).
The entire PAR in both Timor-Leste and the Solomon Islands experienced
stable transmission. More than half of the population (59%) in Asia-Pacific
is at risk of some level of vivax malaria transmission and the 215 million
people at risk was 8.7% of the global PAR.
Vectors. Of the 26 potential vector species of P. vivax (Table 1.2), we
predict that 16 are DVS that occur in Asia-Pacific (Anopheles aconitus,
An. annularis, An. balabacensis, An. barbirostris complex, An. dirus complex,
An. farauti complex, An. flavirostris, An. koliensis, An. lesteri, An. leucosphyrus &
An. latens (sister species grouped together here due to known mis-identification problems within the current literature), Maculatus Group, An. minimus
complex, An. punctulatus complex, An. sinensis complex, An. subpictus complex
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and An. sundaicus complex), six of which are found only in Asia-Pacific
(An. balabacensis, An. farauti complex, An. flavirostris, An. koliensis, An. leucosphyrus & An. latens, and the Punctulatus Group) (Sinka et al., 2011). The
predicted distributions of the DVS in this region are shown in Fig. 1.9B.
For the 16 Asia-Pacific DVS, 9052 unique georeferenced occurrence
records were assembled. The most data-rich species/species complexes
were the An. farauti (n = 1737), An. subpictus (n = 1143) and An. barbirostris
(n = 1064) complexes; and the most data-poor were An. leucosphyrus &
An. latens (n = 12). Occurrence data were reported from all seven PvMECs in
this region. Most of the data originated from Papua New Guinea (n = 1503
sites), followed by Indonesia (n = 890), Solomon Islands (n = 160), Malaysia
(n = 145), the Philippines (n = 124), Vanuatu (n = 36) and Timor-Leste
(n = 1). Given the heterogeneity in vector distribution in this region,
improved data collection from many of these countries would improve the
fidelity of the predicted distributions of this complicated region.
The distribution and behaviour of the DVS discussed below are those
that met the criteria for having broad distributions in the region (Fig. 1.9C)
and have been conclusively incriminated as vectors of P. vivax (Table 1.2).
A complete discussion of their ranges and bionomics may be found elsewhere
(Sinka et al., 2011, 2012).The species that were identified as specific vectors
of P. vivax in Asia-Pacific are An. barbirostris s.l., An. farauti s.l., An. koliensis,
An. leucosphyrus & An. latens and An. punctulatus s. l.
Anopheles barbirostris s.l. is predicted to occur across large areas of inland
Sumatra and Borneo. It is typically a highland species, but is also found in
coastal regions (e.g. western Timor). Adult females of this species complex
tend to feed outdoors on animals during dusk and night time, bringing its
significance as a vector of malaria into question. Further molecular analysis
and identification of the sibling species is needed to determine if variations observed in biting behaviours are due to plasticity within a species
or differences amongst different species in the complex. A variety of larval
habitats are also observed for An. barbirostris s.l. Though they are typically
considered swamp breeds, a variety of water depth, size, light intensity and
movement has been observed. This variation may again be due to the differences among species within the complex rather than the plasticity of a
single species.
Anopheles farauti s.l., An. koliensis, and An. punctulatus s.l. are in sympatry across
most of the islands of New Guinea, New Britain and into the Solomon Islands.
All three are found within the Punctulatus Group.There are two sibling species
in the Punctulatus Complex: An. punctulatus s.s. and Anopheles sp. near punctulatus.

54

Katherine E. Battle et al.

The latter of the two species is relatively uncommon, whereas An. punctulatus
s.s. is reportedly widespread and an important vector on the island of New
Guinea. The distribution of An. punctulatus s.s. spans eastern Indonesia, Papua
New Guinea and the Solomon Islands. Adult females feed readily on humans
outdoors or occasionally indoors.Those that feed indoors may rest there, but are
more likely to exit to find an outdoor resting spot. Peak biting times vary based
on the geographic location.The larvae of An. punctulatus s.s. thrive in temporary
pools that result from disturbed ecology. The habitats tend to be small, shallow,
sunlit pools of water that may be turbid, but never brackish.
The distribution of the eight cryptic species of the Farauti Complex
is largely dependent on the species’ tolerance of salinity such that some
members are coastal species (e.g. An. farauti s.s.) while others are restricted
to inland areas with freshwater larval habitats (e.g. Anopheles hinesorum). The
feeding habits of An. farauti s.l. also vary; host preference changes based on
the availability of hosts and resting may be dependent on where feeding
occurred. Peak biting times fluctuate with location, but it should be noted
that daytime biting may occur. The larval habitats of members of the complex are typically in natural rain-fed water bodies, but artificial containers
such as water drums or coconut shells may also be used. The habitats range
in salinity and light intensity due to the wide geographic distribution of the
species complex.
The predicted distribution of An. koliensis is similar to that of the Punctulatus Complex. The adult females tend to be anthropophilic, but will feed
on other animal hosts. Although females may go indoors in search of a host,
resting typically occurs outdoors. Feeding can occur throughout the night,
with variable peak times based on location. The larval habitats of An. koliensis are intermediate between those of An. farauti s.l. and An. punctulatus
s.l. and are generally associated with permanent freshwater bodies in open
grassland such as irrigation ditches.
Anopheles leucosphyrus and An. latens are sister species of the Leucosphyrus Complex. Both species are found in forested areas with the former on
the island of Sumatra and the latter on the southern portions of the Thai
and Malaysian Peninsula and parts of Borneo. Both species are considered to
be important vectors of malaria and were long thought of as the same species until molecular and cross-mating studies distinguished between them
(Baimai et al., 1988). Little is known of the bionomics of An. leucosphyrus
s.s. because much of the literature on ‘An. leucosphyrus’ is now known to
refer to An. latens. The species has been shown to bite humans both inside
and outside, however. Anopheles latens bites throughout the night with peak
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times that vary based on the seasonal climate and location. Its larval habitats
include shaded temporary pools found in the forest such as swamps, stump
ground holes or wheel tracks.
The bionomics of the DVS in Asia-Pacific are as variable as in mainland
Asia. This is due to variation observed both within species complexes and
among separate species. Such variations increase the challenge of developing a single universal vector control strategy across the region, however, a
combination of methods could prove effective (Lindsay et al., 2004).
Asia-Pacific summary. The vivax malaria problem in Asia-Pacific is
complex and presents a variety of challenges to control. Indonesia and the
Philippines are densely populated over large land masses (Fig. 1.8B) and
P. vivax is predicted to be endemic across most of their national territories. They have the fourth and fifth largest PAR estimates globally with
129 million at risk in Indonesia and 50 million in the Philippines. Some
of the highest predicted PvPR1–99 values were also observed in this region
(Fig. 1.3B1). As in the Asia regions, it is in these areas, where intense P. vivax
transmission occurs (e.g. Indonesia and Papua New Guinea), where drug
resistance is emerging and malaria cases of equivalent clinical severity to P.
falciparum have been observed (Baird, 2004; Pukrittayakamee et al., 2004;Tjitra
et al., 2008; Price et al., 2009).This and the large areas of unstable transmission
make this region a worthy and vital candidate for research, control and eventually elimination efforts; four of the seven PvMECs have already declared
their status of working towards elimination: Malaysia, the Philippines, the Solomon Islands and Vanuatu (The Global Health Group and the Malaria Atlas
Project, 2011). Uncertainty estimates, shown in Fig. 1.4B1 and B2, were high
in areas that also displayed high PvPR1–99 estimates (Fig. 1.3B2), such as Papua
New Guinea. While the population-weighted correction shows that parts of
these regions are, for the most part, sparsely populated (Fig. 1.8B), improved
surveillance to facilitate high-resolution mapping will be essential to tackle
the final transmission hotspots of this region as elimination efforts progress.
The vector situation in this region is complex and further research is needed
to differentiate members of species complexes and incriminate those vectors
that are vectors of P. vivax so that appropriate control measures may be taken.

4.3. Americas
The Americas have amongst the highest P. vivax endemicity values in the
world but these typically occur in areas of very low population density, so the
populations at risk are much lower than those found in Asia (Fig. 1.3C1 and
Fig. 1.8C).The diversity of vector species is also less in this region (Fig. 1.9C).
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Defining the limits of transmission. Plasmodium vivax annual clinical incidence data were available from all 19 countries that are considered to be
endemic in the Americas. The most recent year of reporting was 2008 for
the majority of the countries. Guyana, Nicaragua and Panama reported data
up to 2007; Belize, El Salvador, French Guiana and Guatemala provided
data up to 2006 and Colombia’s last year of reporting was 2005.
Endemic areas in this region were estimated to span 9.46 million km2,
most of which were found in the Amazon basin. The majority of the areas at
risk in the Americas (85%; 8.08 million km2) were at stable transmission (Fig.
1.3C1). This indicated that, for the most part, the disease was either endemic
or wholly absent in this region with limited areas at risk of unstable transmission. The transmission level was generally found to be inversely proportional
to the population density: areas experiencing stable transmission were those
of lower population density. For example, the largest area at risk of stable
transmission in a single country was 4.40 million km2 in Brazil, which was
54% of the stable transmission area for the Americas region. However, the
population at stable risk in Brazil was 26% (13.02 million) of the region’s total
PAR of stable transmission. The Americas comprised 53% of the global land
area at stable transmission but only 5% of the population at that level of risk.
Estimating endemicity. There were relatively few PR records and surveys
for the Americas, with 388 unique records available for modelling. The
three most data-rich countries in this region were Brazil (n = 175; 45%),
Venezuela (n = 65; 17%) and Peru (n = 51; 13%), as shown in Fig. 1.3C1.
The predicted prevalence, or PvPR1–99, was highly variable throughout
the Americas. Much of the areas of stable transmission had PRs between 3
and 5%, with isolated areas nearing 0% and others exceeding 7%. Regions of
high prevalence (>7%) were found in Amazonia (Northeast Brazil) and Central America (Nicaragua and Honduras). The uncertainty in the PvPR1–99
predictions was relatively high overall due to the relatively sparse PR survey data in this region (Fig. 1.4C1). However, when population density
was incorporated into the weighted uncertainty calculations, the resulting
uncertainty index was greatly lowered because the areas with stable risk and
high uncertainty predictions had low population densities (Fig. 1.4C2). This
implies that the observed uncertainty has relatively little operational importance at the global scale, although highlights the current lack of precision for
defining high-risk foci in remote Amazonian settings.
Population at risk. The PAR in the Americas was relatively low given the
geographic limits of P. vivax due to low population densities in areas of high
transmission. It was estimated that there were 137.45 million people living
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at risk of P. vivax in the Americas in 2010. The majority of the PAR was in
areas of unstable transmission (64%; 87.66 million) and 36% (49.79 million)
were exposed to stable P. vivax transmission. Brazil had the largest PAR with
45.22 million people living at any risk, which is 26% of its total population
and represents 33% of the region’s PAR). The largest number of people living at stable risk (13.02 million) was in Brazil, followed by Venezuela with
4.43 million at stable risk and 22.87 million total at risk (83% of the national
population and 17% of the regional PAR). Colombia was estimated to have
7.53 million at stable risk and 19.15 million at risk (56% of its total population and 14% of the region’s total). El Salvador, with a PAR 3.17 million, did
not have any individuals living at stable risk. French Guiana (PAR 158,000)
and Suriname (PAR 30,000; the lowest PAR in the region) did not have any
populations living at unstable risk. The portion of the PAR at stable transmission in Belize was also nearly 100%; only 30 individuals out of 220,000
at risk were in unstable transmission areas. Of the 1.5 billion people living at
unstable and 964 million at stable transmission around the globe, 5.8% and
5.2% of those were found in the Americas, respectively.
Vectors. Of the 20 potential vectors (Table 1.2) of P. vivax in the Americas,
nine are considered DVS. These include Anopheles albimanus, An. albitarsis
complex, An. aquasalis, An. darlingi, An. freeborni, An. marajoara, An. nuneztovari complex, An. pseudopunctipennis and An. quadrimaculatus (Sinka et al.,
2010b). The predicted distribution of these species is shown in Fig. 1.9D.
There were 4141 georeferenced spatiotemporally unique occurrence points
obtained for Anopheles DVS from 25 countries in the Americas.Twenty-two
percent of the occurrence records (n = 926) referred to An. darlingi and 20%
(n = 851) to An. albimanus. The remaining species had occurrence data of
between 63 (An. freeborni) and 572 (An. quadrimaculatus s.l.) records. Of the
total number of point locations identified (n = 1509), the greatest number
came from the United States (n = 377), followed by Brazil (n = 304) and
Belize (n = 228). The PvMECs with the fewest point records (<10) were
French Guiana (n = 7), El Salvador (n = 3), Paraguay (n = 2), Guyana
(n = 1), Honduras (n = 1) and Nicaragua (n = 1).
Distribution maps indicate a relatively straightforward vector profile across the PvMECs of the Americas. Of the nine DVS in this region,
An. darlingi and An. albitarsis s.l. met the criteria for further description
because these species are predicted to have a wide distribution in the region
and conclusive supporting evidence indicating transmission of P. vivax in the
wild, indeed, the distribution of An. darlingi is remarkably similar to that of
P. vivax in the region (1.3C2 and 1.9D). Although An. darlingi is considered
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a riverine species inhabiting forest locations, it has been observed to take
advantage of deforestation, exploiting areas with reduced canopy cover compared to those more densely forested locations. The larval habitats of this
species are typically clear and natural water bodies such as slow-flowing, clear
rivers and streams. Adult female An. darlingi are both exo- and endophagic,
though they tend to rest outdoors regardless of where their blood meal was
taken. Host preference also varies within this species as does biting activity
(time of biting), which may adapt to correspond to human behaviour (i.e. late
night human activity influences or causes late night biting by An. darlingi).
The Albitarsis Complex is composed of five sibling species including
the known vectors, An. albitarsis, An. deaneorum and An. marajoara. Members
of this complex exhibit some behaviours that are similar to An. darlingi, for
example, the adult females tend to rest indoors but will bite indiscriminately
without much host preference both indoors and outdoors. The larval habitats tend to be clear, sunlit, freshwater.
The Americas summary. National surveillance data have shown a widespread decrease in morbidity and mortality from both major Plasmodium
species across the American continent since 2000 (WHO/PAHO, 2008).
This is due largely to the successful implementation of integrated vector
management (Roberts et al., 1997; Butler and Roberts, 2000; Rojas et al.,
2001; Killeen et al., 2002; Roberts et al., 2002; Shiff, 2002; WHO/PAHO,
2006) and has led eight of the 21 PvMECs in the Americas (Argentina,
Belize, Costa Rica, El Salvador, Mexico, Nicaragua, Panama and Paraguay)
to target malaria elimination (The Global Health Group and the Malaria
Atlas Project, 2011). However, the prevalence estimates of P. vivax in the
Americas are heterogeneous with isolated areas of intense transmission
(Fig. 1.3C2). Vector occurrence data coverage was uniformly low in the
American PvMECs. Improved vector research in the Americas will advance
the maps of species-specific distributions, which is essential for the continued success of vector management to curb malaria morbidity and mortality. Pockets of high transmission (PvPR > 7%) were observed in large areas
of the region. However, it is important to note that these were generally
in areas with low population estimates. Sparse prevalence data resulted in
high uncertainty estimates in the region that were greatly reduced when
the density of the population in endemic areas was taken into consideration
(Fig. 1.4C). Anopheles darlingi appears to be the primary vector in this region;
however, eight of the potential vectors of P. vivax in this region lack conclusive evidence regarding their potential to transmit the parasite. Therefore,
further research is needed to decisively incriminate the vectors of P. vivax in
the Americas.
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Plasmodium vivax makes up the vast majority of malaria transmission that
occurs in the Americas (Arevalo-Herrera et al., 2010). Survey data from this
region were relatively sparse and records represent a picture of heterogeneous transmission levels. The Americas contributed a small fraction (5.5%)
of global PAR of P. vivax, but comprised nearly a quarter (22%) of the global
area at risk. Areas of high transmission in highly dispersed populations may
present unique challenges to malaria control.To advance elimination efforts,
high-resolution mapping will be needed to accurately illustrate the degree
of heterogeneity in this region and areas that require the greatest resources.
This will demand more data from areas with high predicted prevalence
and uncertainty, such as Honduras and Nicaragua in Central America and
northwest Brazil in South America. Although Brazil is a large and populous
country, its areas of stable transmission occur in sparsely populated regions
of the Amazon basin. In 2010, Brazil had the seventh largest PAR of P. vivax
globally (45 million), the largest area at risk (4.90 million km2) as well as the
largest area at stable risk (4.40 million km2) and, therefore, has an important
role to play in the region’s future of malaria control and elimination.

4.4. Africa+
The estimates for endemicity and populations at risk of P. vivax malaria in
Africa+ (defined here as Africa, Saudi Arabia and Yemen) are mitigated by
the high prevalence of Duffy negativity in these populations, and the vector
situation in this region is relatively straightforward.
Defining the limits of transmission. High P. falciparum endemicity in Africa,
coupled with high prevalences of Duffy negativity, has meant that collection
of P. vivax–specific data has not been a priority in the past. The data available
from which to estimate the limits of P. vivax transmission is, therefore, limited.
Plasmodium vivax annual parasite incidence (PvAPI) data were only available
from six Africa+ countries (13%). The last year of reporting available was
2009 for four countries (Dijbouti, Namibia, South Africa and Swaziland);
whilst for the remaining two countries (Saudi Arabia and Yemen) the last
available reports were from 2006. Based on the limited PvAPI and PvPR data
available for Africa+, and the presence of suitable vectors and climatic conditions, forty-six countries are assumed to be P. vivax endemic in this region.
The area at risk was estimated to span over 22 million km2 of Africa,
Yemen and Saudi Arabia. Despite the historical misconception that P. vivax
is absent from the African continent, 84% of the 22.46 million km2 of land
in the region was at some risk of P. vivax transmission (Fig. 1.3D2). However, the vast majority (92%; 20.60 million km2) of total area at risk was
estimated to house unstable transmission.
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Estimating endemicity. There were 1640 records of prevalence data from
97 sources obtained for Africa+, 79% of which reported an absence of
P. vivax. Approximately 16% of the global PvPR data records used in
the modelling were from surveys conducted in Africa, Yemen and Saudi
Arabia. Ethiopia, Zambia and Sudan were the most data rich countries,
contributing 50% (n = 826), 18% (n = 295) and 18% (n = 290) of the
total data, respectively.
The predicted prevalence estimates were uniformly low for areas at
stable risk in Africa, Yemen and Saudi Arabia as shown in Fig. 1.3D2. The
point estimates of predicted PvPR1–99 rarely exceeded 2%. The uncertainty
of the predictions in this region was also very low (Fig. 1.4D). The incorporation of information regarding the proportion of Duffy negative individuals strengthened the predictions in this area and compensated for the
sparse parasite rate data available from this region (Fig. 1.3D1, Fig. 1.4D and
Fig. 1.7D). Areas with higher PvPR1–99 (Ethiopia, South Sudan and Madagascar) predictions were also found to have the highest uncertainty, likely
because these areas were outside the range of high Duffy negativity and
could not borrow from the certainty conferred by that restriction. As with
the Americas, the uncertainty in Africa+ was reduced in the populationweighted predictions because of the low population density found in parts of
the continent, particularly Madagascar (Fig. 1.4D2). Uncertainty remained
relatively high in the highlands of Ethiopia, which are more densely populated and are therefore important targets for control.
Population at risk. The PAR in Africa+ was low given the large geographic coverage of the region because of the high prevalence of Duffy
negativity (Fig. 1.3D1 and Fig. 1.7D). There were an estimated 86 million
people living at risk of P. vivax in Africa, Yemen and Saudi Arabia in 2010,
which was 3.5% of the global total. More than half (56%), or 48.72 million,
of the PAR were those living in unstable transmission and the remaining
37.66 million (44%) lived in areas at the level of stable transmission. Nine
countries had an estimated PAR of zero, all of which are located in West
Africa: Côte d’Ivoire, Ghana, Guinea, The Gambia, Guinea-Bissau, Senegal,
Sierra Leone and São Tomé and Príncipe. Togo, Equatorial Guinea, Gabon
and Burkina Faso also had a total PAR of less than one thousand individuals.
Thirty-four countries in the Africa+ region had zero individuals at risk of
stable transmission. Of the 12 countries with stable transmission, Madagascar was the only country where the entire PAR (5.23 million) experienced
stable transmission. Madagascar has the fourth highest PAR in the region;
the highest were Ethiopia, Sudan and Yemen with 35.19 million (41% of
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the PAR in the Africa+ region), 14.78 million (17%) and 13.06 million
(15%) people at risk in each, respectively.
Although the high proportion of Duffy-negative individuals in Africa
is thought to result in an absence of the parasite across the continent, evidence of transmission in Africa+ (Guerra et al., 2010; Ménard et al., 2010)
supported the decision to assume stable transmission in all areas of Africa+
that were not excluded by PvAPI data or biological masks. Areas were then
reclassified following PvPR1–99 predictions such that locations with endemicity levels below 1% were reclassified as unstable; this was the majority
of the region. High proportions of Duffy negativity are especially common
among the population of West Africa. Ghana, for example, had a PAR of
24 million individuals when accounting for environmental exclusions and
before the inclusion of Duffy negativity, which subsequently reduced the
PAR of Ghana to zero. The incorporation of the Duffy negativity layer
reduced the PAR of the Africa+ region from 840 million to 86 million,
which is 3.5% of the global PAR of P. vivax.
Vectors. The high impact of malaria on the African continent is largely
due to the efficiency of the African DVS in transmitting P. falciparum. However, P. vivax may also play an important role. As more countries on the continent move towards elimination, there may be in shift in the endemicity of
P. vivax as levels of P. falciparum decline. It is essential to know which vector
species are capable of transmitting P. vivax.
Africa is the home to two of the most efficient vector species of human
malaria: An. gambiae and An. funestus (Gillies and de Meillon, 1968; Coluzzi,
1999). Of the 10 potential vectors of P. vivax in Africa+ (Table 1.2), eight
(Anopheles arabiensis, An. funestus complex, An. gambiae complex, An. Labranchiae, An. melas, An. merus, An. moucheti and An. nili complex (Sinka et al.,
2010a)) are considered to be DVS of human malaria, but their importance
in transmitting P. vivax is still uncertain. For example, it is unclear whether
the forest vector An. moucheti is a poor/non-vector of P. vivax or that this
parasite simply does not exist in areas where this species occurs (Table 1.2).
The distributions of An. arabiensis, An. funestus s.l. and An. gambiae s.l. and
the DVS that occur in Saudi Arabia and Yemen are shown in Fig. 1.9E. Only
the three primary DVS are shown in Africa because of the lack of evidence
of the ability for the other African DVS to transmit P. vivax (Table 1.2). For
the African DVS there were 8338 spatially and temporally unique occurrence records. The majority of these occurrence records were obtained for
An. funestus s.l. (n = 2692), An. arabiensis (n = 2301) and An. gambiae s.l.
(n = 2291). Point data were obtained from 44 countries.The largest number
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of point records per country were from Kenya (n = 757), followed by Tanzania and Cameroon (n = 383 for both nations). For the most part, the
other countries on the continent had less than 100 point records, with
the exception of Burkina Faso (n = 310), Equatorial Guinea (n = 113),
Ghana (n = 106), Madagascar (n = 198), Mali (n = 166), Nigeria (n = 190),
Senegal (n = 209), Sudan (n = 125), the Gambia (n = 192) and Uganda
(n = 135). African countries classified as P. vivax endemic that had very
few (≤5) vector occurrence point records were Central African Republic
(n = 3), Congo (n = 2), Liberia (n = 4), Namibia (n = 5) and Togo (n = 1).
The compiled species distribution maps (Fig. 1.9E) illustrate a relatively
straightforward picture of the distribution of the region’s DVS: Anopheles
arabiensis, An. funestus s.l., and An. gambiae s.l. which all have broad distributions in the region and are confirmed vectors of P. vivax. These three DVS
dominate in heterogeneous ranges of different pairs and combinations (of
one another) in such a way that the species are present on their own in only
focused locations. The co-dominant range of the An. funestus complex and
An. gambiae in Central Africa is surrounded by an ‘envelope’ that houses
all three primary DVS, that is further surrounded by An. arabiensis and the
Funestus Complex, and then only An. arabiensis on the periphery. Anopheles arabiensis tolerates drier environments and is therefore absent from the
forested areas of western Central Africa. The An. funestus complex distribution indicates a presence throughout all of sub-Saharan Africa, including
Madagascar, but excluding much of southern Africa. Anopheles gambiae has a
more complex distribution across a band from East (including Madagascar)
to West Africa.
The bionomics of all the African DVS of malaria are summarised in full
elsewhere (Sinka et al., 2010a). Here, we briefly describe the behaviours of
those three DVS identified as potential P. vivax vectors in the region. Anopheles arabiensis, An. funestus s.l., and An. gambiae s.l. are known to be primary
vectors of P. falciparum, but have also been incriminated as vectors of P. vivax
through the detection P. vivax circumsporozoite proteins in wild-caught
specimens (Table 1.2). Anopheles arabiensis is often described as zoophilic,
exophagic and exophilic, yet its behaviour appears to be quite variable,
depending on location. For example, An. arabiensis found in West Africa
are generally more anthropophilic and endophagic than those in the East.
Such behavioural variability may enhance this species’ ability to transmit P.
vivax (or any human malaria) allowing it to adapt to avoid control methods
such as IRS. Moreover, with peak biting times ranging from evening (1900)
to early morning (0300), An. arabiensis may also avoid control via ITNs.
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Anopheles arabiensis tends to be found in drier climates within Africa and
larval habitats are typically small, temporary, clear, sunlit freshwater pools
similar to those of An. gambiae s.l. However, An. arabiensis larvae have also
been sampled from large or small man-made water bodies, including rice
fields, as well as flowing or even brackish waters.
There is less variation observed in the bionomics of An. funestus s.l.
relative to An. arabiensis. This species is known to be highly anthropophilic
and endophilic and have a late biting time (after 2200), making IRS or
ITNs highly effective interventions (although pyrethroid resistance has now
been reported (Hargreaves et al., 2000; Coetzee and Fontenille, 2004)). The
larval habitats of the Funestus Complex tend to be large, permanent (or
semi-permanent) bodies of freshwater such as a pond, lake edge or rice
field, where the larvae use emergent plants as protection against predation.
There is some variation in the behaviour of members of the complex and
further investigations using molecular identification methods are needed
to determine the distribution of the different subtypes and the bionomics
they exhibit.
Anopheles gambiae s.l. is perhaps the most well-known vector of human
malaria and the most studied. It occupies a wide geographic range and is
considered to be a highly efficient vector because of its highly anthropophilic biting behaviour and relatively long adult life stage. Females generally feed late at night indoors and also rest indoors, again making IRS
and ITNs successful intervention strategies. However, in studies comparing feeding and resting location preference, An. gambiae s.s. exhibited
both indoor and outdoor feeding and resting habits (Sinka et al., 2010a).
This is likely ascribed to different chromosomal and molecular forms now
identified within the species (Bockarie et al., 1993). The larval habitats of
An. gambiae s.l. were long thought to be restricted to clear sunlit, temporary
pools such as puddles or hoof prints, however, larvae have been reported
from turbid and even polluted water and from large semi-permanent water
sources such as rice fields. The variation of larval habitats is again attributed
to divergences of the chromosomal or molecular forms.
The vector species of P. vivax in Africa occupy wide geographic ranges
across the region and exhibit variation in behaviours both among and
within individual species or species complexes. This may present challenges
for control, yet, the tendency for these species to bite and rest indoors at
night makes control methods such as ITNs effective control strategies.Vivax
malaria is not currently the main focus of malaria research in this region and
incrimination studies on wild populations have yet to be performed on half
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of the potential DVS in this region (Table 1.2). Further research identifying
which anopheline species are the most efficient vectors of this parasite will
be beneficial to the Africa+ region as goals of control and elimination of
P. falciparum are realised and the focus moves to address P. vivax.
Africa+ summary. Estimates of the PAR of P. vivax in Africa, which is
climatically well suited for malaria transmission, were very low, with the
exception of countries around the Horn of Africa. This was because of the
assumption that Duffy negative individuals, found in high frequencies on
the continent (Howes et al., 2011), are refractory to P. vivax infection. This
supposition was incorporated into the model, despite observations of P. vivax
malaria infections in Duffy-negative individuals in Madagascar (Menard
et al., 2010) and on the mainland of the continent (Ryan et al., 2006; Mendes
et al., 2011;Wurtz et al., 2011).While this information contradicts our working assumption of complete protection, there is insufficient evidence to
determine if these are more than just rare occurrences on the continent that
would have a significant effect on the epidemiology of P. vivax in Africa.
Prevalence estimates for Africa are characterised by low predicted values
and high levels of uncertainty (Fig. 1.4D). The PR data from Africa that
served as the input data for the endemicity predictions were sparse, with
the exception of a few regions (Fig. 1.3D1). This is largely because P. vivax
is not the main priority for Africa. There were 753 million people at risk of
stable P. falciparum in Africa in 2010 (Gething et al., 2011a), compared to the
38 million at stable risk P. vivax. However, 30% (228 million) of the 753 million were living in regions of low stable transmission (PfPR2–10 ≤ 5%); the
prevalence of P. falciparum in these areas falls to a point where elimination is viable, the situation of P. vivax will increase relatively, a consequence
of its tendency to be the last parasite standing during elimination efforts
(Garnham, 1951; Yekutiel, 1960; Pampana, 1969; Wernsdorfer et al., 2009;
Tatem et al., 2010).This reinforces the need for increased vector surveillance
and incrimination of species specifically for P. vivax. The endemicity map
(Fig. 1.3D2) presented indicates that while P. vivax is present at very low levels in Africa, it is circulating. Consideration for how those prevalence estimates may be affected by decreasing P. falciparum levels must be considered.

4.5. Areas Where Lack of Geographical Data is Acute
Asia. Although there was thorough coverage of annual clinical incidence
data and a large number of prevalence data records, given the large area of
PvMECs in Central Asia (20.5 million km2), there were still large regions
with a dearth of data (Fig. 1.3A1). These regions are highlighted by the
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uncertainty maps (Fig. 1.4A). India, the nation with the largest PAR of P.
vivax globally, had disproportionately little prevalence data available. Given
that parts of India are predicted to experience intense transmission, highresolution mapping is needed to identify foci of transmission and this will
only be achieved through improved surveillance coverage or the release of
data that have not been previously shared. The uncertainty map also highlights lack of data in Myanmar. Regions of high uncertainty, which were
also present in the population-weighted estimates, correspond with areas
plotted to be highly endemic (PvPR1–99 > 7%). Improved certainty in predictions in this country would be beneficial as neighbouring Thailand and
China work towards malaria elimination. There would also be utility in the
provision of contemporary data as progress towards elimination is made (e.g.
in China) and transmission dynamics are therefore altered.
Asia-Pacific. Coverage of annual clinical incidence and prevalence survey data was relatively strong for this region (Fig. 1.3B1). However, the
vast majority of the prevalence data originated from Indonesia. Sites on
the island of New Guinea and parts of Borneo had very sparse prevalence
data and were therefore predicted with greater uncertainty (Fig. 1.4B1 and
B2). These regions have some of the most intense P. vivax transmission settings in the world. Improved surveillance would help localise hotspots and
generate prime targets for control. The Philippines should also be noted as
being a region with high uncertainty that was retained even after accounting for population density in the predictions. The smaller islands of this
region would benefit from improved vector data collection since many had
very little vector data available. This would improve the fidelity of the species distribution models in this region to better inform control decisions.
The Americas. Relative to other regions with stable P. vivax transmission,
there were very little prevalence data available for this region (Fig. 1.3C1).
Improved PR data from this part of the world, particularly those countries
with intense transmission (Brazil, Honduras and Nicaragua), would benefit P.
vivax mapping efforts. High-resolution mapping is needed to accurately map
these highly focalized transmission settings, and this will require broad coverage survey data.There was good vector data coverage in this region, which
is likely linked to the research and implementation of successful vector control efforts in the Americas. However, data collection on vector occurrence
could be further improved. Some of the countries with the highest transmission (Honduras and Nicaragua) had the fewest occurrence records available.
Africa+.The P. vivax data available from Africa+ were also sparse, a reflection of the perception that the parasite is largely absent from the continent
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(Fig. 1.3D1). In this region, the importance of P. vivax is overshadowed by P.
falciparum and as such is not recorded in many countries. However, P. vivax
infection has been observed in Duffy-positive and -negative individuals in
the region, hence, it would be prudent for countries to monitor the prevalence of the parasite. While prevalence data were lacking from the region as
a whole, the areas that would benefit most from improved surveillance are
those with higher intensity transmission: Ethiopia, Madagascar and Somalia.
This would reduce the uncertainty of the predictions and allow for better
monitoring of control efforts. Lastly, the vector data available for the DVS
in the region was relatively poor. Although the vector profile of Africa+
is straightforward, increased occurrence records may capture intricacies in
distribution patterns and help distinguish vector and non-vector species of
species complexes.

5. DISCUSSION
Plasmodium vivax malaria imposes serious public health burdens and
is the most widespread of all the human malarias, particularly in women
and children in poorly resourced communities (Poespoprodjo et al., 2008,
2009). Robust evidence demonstrates that P. vivax, despite long-held convention, is not a ‘benign’ infection (Baird, 2007; Price et al., 2007b). Moreover, studies show that 60-year-old drugs used to treat vivax malaria are
failing throughout much of the P. vivax-endemic world (Baird, 2009; Price
et al., 2009). The hypnozoitocidal component of that treatment, primaquine, is a deeply flawed therapy due to the threat it imposes to G6PD
deficient patients (Baird, 2007). The reader is also referred to the chapter
by Howes et al. that appears elsewhere in this thematic issue of Advances in
Parasitology (Chapter 4, Volume 81). These issues are brought into focus as
international targets, such as the Millennium Development Goals (http://
www.mdgmonitor.org/), are developed to halt or mitigate malaria incidence and further goals are set for the elimination of the disease (WHO,
2007; Feachem and Sabot, 2008; The Global Health Group and the Malaria
Atlas Project, 2011). Neglect of the impact and study of P. vivax is incompatible with these expressed goals.
The P. vivax PR estimates reviewed here are, across the American,
African and Asian regions, uniformly low in comparison with PR estimates derived for P. falciparum (Gething et al., 2011a). The PR spectrum for
P. vivax ranges from 0% to 7%, whereas for P. falciparum, it is 0 to 70%. This
seems to imply P. falciparum transmission is an order-of-magnitude greater,
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but this is potentially misleading.The absolute prevalence of P. vivax in heavily
endemic zones may also reach or exceed 70%. Relatively low parasite densities in blood (arising from its strict preference for reticulocytes) may lead
to high rates of false-negative diagnoses by microscopy or rapid diagnostic tests (RDTs) (Mueller et al., 2009a). Microscopic diagnoses very often
underestimate the true prevalence of P. vivax in blood in both high- and
low-transmission settings (Mueller et al., 2009b; da Silva et al., 2010; Harris
et al., 2010; Katsuragawa et al., 2010; Steenkeste et al., 2010). Further details
regarding the diagnosis of P. vivax may be found in a review elsewhere in
this thematic volume of Advances in Parasitology (Chapter 4, Volume 80).
Missed diagnosis is important in mixed species infections where P. vivax may
be a minor contributor to parasitaemia and often overlooked (Mayxay et al.,
2004). There is no proven evidence that this is due to cross-species immunity, rather that plasmodia species are mutually suppressive in mixed infections (Richie, 1988).While P. falciparum tends to dominate P. vivax, infection
with P. vivax reduces the intensity of falciparum infections (Snounou and
White, 2004). Mixed infections are complex and often under-diagnosed
(Mayxay et al., 2004) and it is difficult to interpret the effect they may
have on prevalence estimates. The reader is referred to a review of acquired
immunity to P. vivax provided in this volume (Chapter 3,Volume 81).
The difference in PR spectrums between P. vivax and P. falciparum could
also be a reflection of the age range used as the input data for the endemicity model.To model endemicity, P. vivax predictions were standardised across
the 1–99 age range, rather than the 2–10 years of age range, which was
used for P. falciparum (Gething et al., 2011a). Malaria transmission peaks in
2–10-year olds and, therefore, the use of the 1–99-year age range ‘dilutes’ the
prevalence estimates. Regardless, it is evident that the association between
the risk of disease and parasite prevalence is markedly different for P. vivax
than P. falciparum, with significant risk of P. vivax disease at lower parasite
densities.
The maps reviewed here represent progress towards an improved understanding of the epidemiology of this unique malaria parasite. Included
in this work is the first ever P. vivax-specific global endemicity map and
updated limits of transmission.These maps are intended to aid control strategy formulation and operational decision-making. Stratification by transmission intensity has been supported by mathematical modelling in the
context of P. falciparum management (Smith et al., 2006, 2008; Okell et al.,
2008; Smith and Hay, 2009; Chitnis et al., 2010a, 2010b; Griffin et al., 2010;
Ross et al., 2011), but P. vivax is rarely differentiated by endemicity level.
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Consensus has yet to be reached in defining suitable control-oriented strata
for P. vivax. Without such stratified control, there has been little impetus
to fill that knowledge gap and generate reliable stratified risk maps. These
P. vivax mapping efforts may also be unified with those for P. falciparum (Hay
et al., 2009; Gething et al., 2011a) to help rectify this and elucidate where
control efforts of the two parasites can be amalgamated. An example of such
is the potential use of artemisinin-combination therapy (ACT) as presumptive treatment for diagnosed malaria in co-endemic areas discussed in the
review of the use of anti-malarial drugs to reduce P. vivax transmission that
is provided elsewhere in this volume (Chapter 5).
Primaquine, the only drug currently licensed to treat the liver stage of
the parasite is contraindicated in individuals with G6PD deficiency. The
map of P. vivax endemicity is an important complement to the recently
developed map of G6PD deficiency (Howes et al., 2012) and will help to
identify areas with high prevalence of both P. vivax and G6PD deficiency.
Overlaying these is essential for estimating the potential risk of adverse
outcomes that could occur from treatment with primaquine in areas where
G6PD deficiency testing cannot be guaranteed (Ruwende and Hill, 1998;
Cappellini and Fiorelli, 2008). The reader is again referred to a review of
G6PD deficiency that details the geographic distribution, genetic variants
and the implication of primaquine therapy provided elsewhere in this thematic issue of Advances in Parasitology (Chapter 4,Volume 81).
Plasmodium vivax endemicity maps provide bench-marks for progress in
control and elimination. This information is increasingly needed by international organizations and groups that are once again assessing the prospect
of eradication of all species of human malaria (Lines et al., 2007; Feachem
and Sabot, 2008; Greenwood, 2008; RBMP, 2008; Mendis et al., 2009;
Malaria Eradication Research Agenda, 2011b). At present, these maps are
of particular importance outside of Africa, where P. vivax is the primary
threat. Thirty of the 95 PvMECs are in Asia and their populations comprise
91% of the global PAR of P. vivax. Knowledge of the global distribution
and impact of P. vivax is also important to estimate market size and investment priorities for those developing targets for drug (Malaria Eradication
Research Agenda, 2011a) and vaccine (Brown et al., 2009; Malaria Eradication Research Agenda, 2011c) research and development. The maps also
facilitate national priority setting and advocacy.
The maps of dominant vector species of human malaria presented here
(Fig. 1.9) and information regarding the potential vector species of P. vivax
(Table 1.2) highlight a further knowledge gap in our understanding of P.

The Global Public Health Significance of Plasmodium vivax

69

vivax compared to P. falciparum. Classification of anopheline species as vectors of malaria has typically meant vectors of P. falciparum malaria. This is
most evident in the Africa+ region, but conclusive information is also missing from the Asian and American regions, where P. vivax is the dominant
parasite. In many countries, the status of vector species is determined by
absence of evidence rather than decisive evidence of absence of the parasite. The research into transmission of P. vivax is lagging behind that of P.
falciparum. Improved vector surveillance would benefit all regions, but not
without incrimination studies that focus specifically on P. vivax.
Currently, the cartographic foundations for estimating the public health
burden of P. vivax do not exist and this is perhaps the highest priority for
moving forward. The link between P. vivax prevalence and clinical burden
must be established for regions where the disease is monoendemic as well
as where it is sympatric with P. falciparum. National estimates of P. vivax rely
on routine case reporting sources that vary in their fidelity and are often
crudely distinguished from P. falciparum (WHO, 2011). Cartographic estimates of P. vivax burden would provide valuable information regarding the
impact of the disease independent of inherent biases that may accompany
health system data (Gupta et al., 2009; Rowe et al., 2009; Hay et al., 2010a,
2010b; Malaria Eradication Research Agenda, 2011b; Mueller et al., 2011).
There is also a need to define the burden of P. vivax in clinically vulnerable
groups such as pregnant women (Nosten et al., 1999; Mueller et al., 2009a)
and, most notably, children. To estimate the burden of P. vivax, it will first be
necessary to gain a better understanding of the impact of relapsing infections
on prevalence. The degree to which relapses contribute to clinical disease
is known to vary geographically, but the cause and pattern of the variation
is still poorly understood (Battle et al., 2011; Betuela et al., 2011; White,
2011) and calls for further investigation. The extent to which P. falciparum
affects the burden of P. vivax remains unknown, and now emerges as an
important question in elimination strategy (Maitland et al., 1996, 1997;
Snounou and White, 2004; Genton et al., 2008).
This chapter described the global public health significance of P. vivax in
light of new cartographic technology and evidence, along with the fundamentally important emerging understanding of the infection as threatens to
life. The parasite occurs across a broader geographic range, in more diverse
habitats, in more anopheline vector species, and threatens more people
than P. falciparum.Vivax malaria is an overwhelmingly Asian and Asia-Pacific
problem, home to 91% of the 2.49 billion PAR, dozens of mosquito vector
species, and endemic habitats as distinct as the temperate Korean peninsula

70

Katherine E. Battle et al.

and tropical New Guinea. This is the same region where treatments are
failing due to drug resistance or reluctance to use threatening and impractical treatments like primaquine.Vivax malaria today threatens many people
with very serious illness and is especially difficult to prevent and treat. The
evidence presented in this chapter and others in this thematic issue disclaim
the long-held presumption of inconsequence with infection by P. vivax.

6. METHODS
The full methods that would allow the reader to reproduce these maps
are given in Gething et al. (2012) and Sinka et al. (2010b). Here, we bring
together the full suite of methodologies and present a set of summaries that
highlight the data used and the assumptions made to allow the value of the
resulting estimates to be assessed.

6.1. Defining the Limits of P. vivax Transmission
To adequately assess the global burden of P. vivax, the limits of the infection
and the global distribution of risk must first be identified. Knowledge of the
spatial distribution, and the clinical incidence within those limits, provide a
foundation on which control efforts and measures of progress can be based.
MAP began these efforts through defining the spatial limits of infection and
the PAR, informed by ecological variables and the distribution of Duffy
negative individuals, and then applied those limits to mapping the transmission and varying levels of P. vivax endemicity globally.
6.1.1. International Limits of P. vivax
The global spatial limits of P. vivax malaria were first defined for 2009
(Guerra et al., 2010) and the methods and results have since been updated
for 2010 (Gething et al., 2012). A list of 95 P. vivax malaria endemic countries (PvMECs), illustrated in Fig. 1.10A1–D1, was identified using previous
methods based on international health and travel guidelines (Centers for
Disease Control and Prevention, 2009; Guerra et al., 2010; WHO, 2010b;
Gething et al., 2011a). The PvMECs were grouped into three regions: the
Americas; Africa, Saudi Arabia and Yemen (Africa+); and Central and South
East Asia (CSE Asia), which was further divided into Asia and Asia-Pacific
in order to resolve PAR estimates (referred to here as Asia and Asia-Pacific)
(Fig. 1.2). The borders of these countries, along with national survey information and relevant, published sources and personal communications,
defined the first version of the P. vivax spatial limits map (Guerra et al., 2010).
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Figure 1.10 Map sequence illustrating the different exclusion layers applied by
region. Maps are shown by region: Asia (A), Asia-Pacific (B), the Americas (C) and Africa+.
Panel 1 = all regions of the regional P. vivax endemic countries; 2 = downgrading or
exclusion of risk informed by annual parasite incidence data (PvAPI); 3 = additional
exclusion of risk informed by the biological temperature mask; 4 = additional downgrading or exclusion of risk informed by the aridity mask; 5 = additional downgrading or exclusion of risk informed by medical intelligence and international travel and
health guidelines; 6 = the final limits definition after additionally downgrading risk in
stable areas predicted to have very low prevalence by the model-based geostatistics
(MBG) model. Stable transmission is shown in red, unstable transmission in pink, P. vivax
malaria free areas in grey and countries non-endemic for P. vivax or outside of the region
in white. For interpretation of the references to colour in this figure legend, the reader is
referred to the online version of this book.

PvAPI data, which report the number of confirmed P. vivax malaria cases
per administrative unit per 1000 people per annum (p.a.) from PvMECs,
were used to further constrain the spatial limits of infection (Fig. 1.10A2–
D2). PvAPI data were obtained from a variety of sources which are provided
in detail elsewhere (Gething et al., 2012). Data were unavailable for 41 of
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Figure 1.10, cont’d

the 95 PvMECs, which were all within the Africa+ region, with the exception of Uzbekistan. Ideally, the PvAPI data were available per administrative
unit per year with each record containing information regarding the number of people in each administrative unit and the number of P. falciparum
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and P. vivax cases. When necessary, the missing data were extrapolated from
PvAPI data estimates from preceding years or parasite species ratios confirmed by alternative sources. The aim was to obtain data for the four most
recent previous years (up to 2010) at the second administrative (ADMIN2)
level (or third, ADMIN3, if data were available). To map the PvAPI data,
the information was reconciled to the digital administrative boundaries
available from the 2009 Global Administrative Unit Layers (GAUL) from
the Food and Agriculture Association of the United Nations (FAO) within
the Food Security for Action Programme (FAO, 2008). PvAPI data were
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arranged to classify areas at risk into three categories: malaria free, unstable
(<0.1 cases per 1000 p.a.) or stable (≥0.1 cases per 1000 p.a.) transmission.
These values were based on the Global Malaria Eradication Programme
classifications; API values of <0.1‰ were considered a reliable indication to
cease IRS and to shift to the consolidation phase of eradication (Pampana,
1969; Yekutiel, 1980; Guerra et al., 2008; Hay et al., 2008). This followed
a transition from a cut off of 0.5 cases per 1000 p.a., which was deemed
less reliable because malaria would at times return after the cessation for
spraying at an API of 0.5‰ (Guerra et al., 2008). This was likely because
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surveillance, whether passive or active, was not wholly reliable or reflective
of true endemicity levels. The more conservative categorization that is also
applied here, of unstable transmission equating to less than 0.1 cases per
1000 p.a. allowed for less confidence in the fidelity of the prevalence source
information and accounted for inaccuracies in district or provincial level
reporting (Snow et al., 2005; Erhart et al., 2007; Sharma, 2007).
Biological masks were applied to further constrain the risk in the P. vivax
endemic regions. Environmental conditions can suppress malaria transmission by limiting various components of the transmission cycle. Temperature has been shown to affect vector survival, emergence and feeding rates
(Ross, 1911; Detinova, 1962; Mahmood and Reisen, 1981; Ahumada et al.,
2004).The most limiting effect of temperature on malaria transmission is the
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interaction between vector lifespan and the length of the sporogonic cycle;
as temperature varies throughout the year, as does the length of the extrinsic incubation period during which the parasite matures to the sporozoite
stage within the gut of the mosquito (Nikolaev, 1935). For transmission to
occur, the anopheline population must survive long enough for sporogony
of the parasite to occur. A model that assesses the effects of temperature on
P. vivax over time (Gething et al., 2011b) was used to generate a grid of
temperature suitability proportional to vectorial capacity, a measure of transmission potential (Garrett-Jones, 1964; Smith and McKenzie, 2004). Daily
vector survival was calculated as a function of local temperature and vector
lifespan was assumed to be 1 month (Kiszewski et al., 2004), with exceptions being made for areas with longer living species (Anopheles sergentii and
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An. superpictus) (Guerra et al., 2008; Sinka et al., 2010a). The interaction
between vector lifespan and the length of the sporogonic cycle was modelled
for each pixel of the temperature suitability grid (Fig. 1.5), so that pixels in
which there was no time during the year that sporogony could be completed
were classified as being at no risk for P. vivax transmission (Fig. 1.10A3–D3).
A second environmental driver of suitability for P. vivax transmission
is availability of sufficient moisture. A mask of aridity was used to exclude
areas where arid conditions would preclude anopheline survival at all life
stages (Shililu et al., 2004; Gray and Bradley, 2005). Arid areas were identified
using the global GlobCover Land Cover product (ESA/ESA GlobCover
Project, led by MEDIAS-France/POSTEL) (Bicheron et al., 2008). The
aridity mask (Fig. 1.6) was treated differently from the temperature mask
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to accommodate for the possibility of human and vector species adapting
to arid conditions so that risk classes were downgraded depending on the
land cover. GlobCover bare areas classified as stable risk according to the
PvAPI were downgraded to unstable, and unstable risk was stepped down
to malaria free (Fig. 1.10A4–D4).
Medical intelligence was also used to refine the limits of P. vivax risk
(Fig. 1.10A5–D5). International travel guidelines (Centers for Disease
Control and Prevention, 2009; WHO, 2010b) and data obtained through
personal communications were applied to identify urban and sub-national
malaria free-areas. Urban areas have less malaria transmission than rural
areas because of the distinct ecological conditions that result from a manmade environment (Hay et al., 2005; Tatem et al., 2008). Different species
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of Anopheles mosquitoes respond at varying degrees, but urbanisation has
been shown to reduce malaria transmission across Africa and in parts of the
Americas (Hay et al., 2005; de Castro et al., 2006). In Asia, a principal vector, An. stephensi, has adapted to urban environments by breeding in artificial
water collections (Sharma et al., 1993; Sinka et al., 2011) to the extent that
stable transmission has been observed in the majority of cities (70 out of
86 cities examined) in India reporting annual parasite index data (Akhtar
et al., 2009). Anopheles culicifacies s.l. has also been shown to transmit malaria
in urban settings, but population densities and sporozoite rates indicate that
this species is more affected by the environmental changes of urban areas
(Nalin et al., 1985; Sharma et al., 1993; Sharma, 1995; Sinka et al., 2011).
Therefore, it was assumed that urban transmission was maintained by only
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An. stephensi. Cities specified as being malaria free by the international travel
and health guidelines (Centers for Disease Control and Prevention, 2009;
WHO, 2010b) or other sources were mapped using the GRUMP urban
extent layer (Balk et al., 2006). Urban areas outside of the range of An. stephensi
were classified as being at no risk of P. vivax transmission and areas within
the vector species’ range were down-graded by one risk level (stable to
unstable; unstable to malaria free) accordingly. In addition to urban areas,
some administrative areas, such as islands, were also declared malaria free by
the international travel and health guidelines and a few specific personal
communications. These areas were also classified as no risk if they were not
already specified as such by the PvAPI layer. The final limits for each region
are shown in Fig. 1.10A6–D6.
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6.1.2. The Availability of PvAPI Data by Region
Plasmodium vivax API data were available from 53 countries at a variety of
administrative levels from years ranging between 2002 and 2010.
Asia. Annual parasite index data were aggregated at a variety of administrative levels. Azerbaijan, Bhutan, Cambodia, Kyrgyzstan and Thailand provided data at the first administrative (ADMIN1) level. China reported data
from areas known to have little to no transmission regions at ADMIN1, and
at ADMIN3 in the remaining areas. Myanmar and Nepal reported all data
from ADMIN3 units. The remaining countries (Afghanistan, Bangladesh,
Georgia, India, Iran, Iraq, Lao PDR, Pakistan, Republic of Korea, Sri Lanka,
Tajikistan, Turkey and Viet Nam) collected PvAPI data from ADMIN2
units. PvAPI data were available from 4443 risk units in Asia.
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Asia-Pacific. Annual parasite index data were provided for all of the P. vivax
endemic countries in Asia-Pacific. Only Malaysia provided data up until 2010.
Indonesia and Timor-Leste had data until 2008 available and 2007 was the
last reporting year for the remaining countries. Malaysia, the Solomon Islands,
Timor-Leste and Vanuatu provided data at the ADMIN1 level and Indonesia,
Papua New Guinea and the Philippines reported data from ADMIN2 units.
PvAPI data were obtained from a total of 559 risk units in Asia-Pacific.
The Americas. PvAPI data were available from all PvMECs in the
Americas. For the years reported, which varied by country, six countries
(Belize, El Salvador, Guatemala, Guyana, Nicaragua and Suriname) reported
data at the first administrative (ADMIN1) level and Venezuela reported data
at the ADMIN1 and ADMIN2 level. Eleven countries (Argentina, Bolivia,
Brazil, Colombia, Costa Rica, Ecuador, French Guiana, Honduras, Mexico,
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Panama and Paraguay) reported ADMIN2 data and Peru reported data from
ADMIN3 units. Data were available for a total of 12,514 administrative (or
risk) units in the Americas.
Africa+. PvAPI data were aggregated at a variety of levels by the six (out
of 46) PvMECs that reported data in the region. For the years of available data, Dijbouti, Saudi Arabia and Yemen reported ADMIN1 level data,
Namibia reported from a mix of ADMIN1 and ADMIN2 units, and South
Africa and Swaziland had data available at the ADMIN2 level. Data were
provided for a total of 377 risk units for the Africa+ region.
6.1.3. The Global Distribution of the Duffy Blood Group
The distribution of Duffy-negative populations was used as another exclusion layer to constrain the limits of P. vivax transmission (Fig. 1.7).The reader
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is again referred to a detailed review of the effect of the lacking Duffy antigen on resistance to P. vivax provided in this thematic issue of Advances in
Parasitology (Chapter 2, Volume 81). The Duffy antigen refers to a receptor
expressed on the surface of red blood cells, which P. vivax has been shown to
be dependent upon for erythrocytic invasion (Miller et al., 1976; Barnwell
et al., 1989; Wertheimer and Barnwell, 1989). Duffy-negative individuals,
who lack the antigen, are therefore largely refractory to P. vivax infection and
high frequencies of the phenotype are presumed to suppress P. vivax endemicity in areas that would otherwise be well suited for transmission. A continuous map of the Duffy-negative phenotype, described in detail elsewhere
(Howes et al., 2011) and briefly here, was used as the exclusion surface.
To model the global distribution of the Duffy-negative phenotype, a database of Duffy blood group surveys was assembled. Surveys of Duffy-variant
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frequencies were compiled from systematic searches of published literature,
personal communications and sources obtained through previously published databases (Mourant et al., 1976; Cavalli-Sforza et al., 1994). Surveys
dating back to 1950, when the blood group was first described (Cutbush
and Mollison, 1950), were included. Results were refined so that only
population-based surveys were used and potentially biased samples were
removed. Survey data were geopositioned following guidelines described
previously by MAP (Guerra et al., 2007).
In addition to the frequency of the blood group variants, the diagnostic method used in each survey was recorded to classify the type of
information provided to ultimately inform the model. The Duffy antigen
has two main variant forms, Fya and Fyb. These differ by a single amino
acid substitution (Gly42Asp), which is encoded in two alleles, FY*A and
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FY*B, that vary based on a single base substitution (G125A) (Zimmerman, 2004; Langhi and Bordin, 2006). A separate single base substitution
in the gene’s promoter region (T-33C) may block the expression of the
gene and result in a null ‘erythrocyte silent’ (ES) phenotype.This mutation
is most commonly associated with the FY*B (FY*BES) allele (the FY*AES
allele is extremely rare) (Langhi and Bordin, 2006; Sellami et al., 2008).
These four alleles (FY*A, FY*B, FY*BES, FY*AES) result in 10 possible
genotypes and four possible phenotypes: Fy(a+b+), Fy(a+b−), Fy(a−b−)
and Fy(a−b−) (Howes et al., 2011). Methods to diagnose Duffy types can
focus on different aspects of the system: the individual polymorphic sites,
the genotype, the presence or absence of the antigen, and which particular type of antigen is being expressed. The assembled data were therefore
grouped into five types according to which diagnostic approach was used:
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i) Genotype, where full genotypes were reported; ii) Phenotype, where full
serological diagnoses (anti-Fya and anti-Fyb sera) were used; iii) Promoter,
if results only stated antigen expression or non-expression (no distinction between Fya and Fyb); iv) Phenotype-a, if only Fya was tested for (no
distinction between Fyb and the negative phenotype); and v) Phenotype-b,
if only Fyb was tested for (no distinction between Fya and the negative
phenotype).
This dataset formed the evidence-base for a geostatistical model used to
predict a continuous map of the prevalence of the Duffy-negative phenotype
[Fy(a−b−)], the phenotype encoded by the FY*BES/FY*BES genotype.The
FY*AES is highly infrequent and so was modelled as a small constant rather
than a spatially variable allele. Although not all of the five data types directly
informed the prevalence of Duffy negativity, the model was able to infer
useful information directly from each (by ruling out certain genotypes),
so all were included as model inputs. To allow this, the model structure
was based on the frequencies of the two loci involved in the system: the
promoter type (determining expression versus non-expression at the T-33C
site) and the coding region (determining the G125A polymorphism). The
Bayesian framework considered the two loci as spatially independent random fields, and used the survey data to map the frequency of the expression
of each variant. Each of the data types informed different aspects of these
loci: some informed both loci and others excluded possible variants. The
model also incorporated a land cover variable to distinguish sub-Saharan
African populations from others on the continent. This was to inform the
model of the high probability of association between silencing mutation of
the Fyb variant and the FY*BES allele, which was observed in high frequencies across sub-Saharan Africa.
The Bayesian model-based geostatistical framework predicted Duffy
group expression frequencies in all geographic locations across a 5 × 5 km
grid to generate a continuous global surface of each variant.The Duffy negativity phenotype was expressed by the squared frequency of the FY*BES
allele. The map reveals that the homozygous null phenotype is highly constrained to sub-Saharan African populations, with localized high-frequency
areas in the Americas. Historical perceptions have supported the assumption that P. vivax is absent from much of the African continent (Rosenberg,
2007). However, evidence of autochthonous transmission within Africa
indicated that areas of the continent should not be excluded a priori. This
map, therefore, provided an evidence-based exclusion layer for Duffy-negative populations resistant to P. vivax infection in Africa.
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6.2. Global Endemicity of P. vivax
6.2.1. P
 . vivax Parasite Rate Data
To map P. vivax malaria endemicity within the limits of stable transmission, in addition to the updated geographic boundaries and corresponding
populations at risk of P. vivax, an updated georeferenced database of P. vivax
parasite rate (PvPR) survey data were compiled. PR was used here because
it is the most ubiquitous of the malariometric measures of risk (Hay et al.,
2009). PvPR data represent the proportion of a randomly sampled population to have detectable P. vivax parasitaemia when screened via microscopy
or RDTs and is the most consistently measured index of malaria endemicity. The final database consisted of unique surveys obtained from published
and unpublished literature sources spanning the period 1985–2010. The
database included information on the survey origin, how the location was
determined (georeferencing method), time period, age group, sample size
and diagnostic method used.
The PvPR database was made up of 9970 spatiotemporally unique
records from 432 different sources. Data were available from 53 countries,
12 of which were in the Americas, 19 in the Africa+ region, 15 in Asia and
7 in Asia-Pacific. There were 44 PvMECs not represented in the database,
most of which were in Africa, with the exception of Argentina, Azerbaijan,
Belize, Bhutan, Korea DPR, El Salvador, Georgia, Guyana, Iran, Kyrgyzstan,
Panama, Paraguay, Republic of Korea and Uzbekistan. Details of the PR
data that were input into the model from each region are given below.
6.2.2. Modelling P. vivax Endemicity
To generate a continuous surface of P. vivax endemicity using PR data, a flexible modelling framework based on model-based geostatistics (MBG) (Diggle
et al., 1998; Diggle and Ribeiro, 2007) was used.With areas of stable transmission converted into a 5 × 5 km grid, MBG models allow for endemicity values
to be predicted at each pixel as a function of the geographically varying mean
of survey values and a weighted average of neighbouring data values. MBG
models are well suited for predicting endemicity values, in this case PRs, for a
number of reasons. First, the mean PR values may be defined as a function of
multiple environmental covariates that influence malaria transmission. Second,
a covariance function may be employed to define the spatial heterogeneity of
the PR data and, in turn, define the appropriate weight for each data point
when generating a prediction. Third, uncertainty can be based on the nature
and density of data surrounding a pixel. Fitting MBG models with Bayesian
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inference and a Markov chain Monte Carlo (MCMC) algorithm produces
uncertainty metrics around the final predictions as well as the model inputs
in the form of predictive posterior distributions (Patil et al., 2011). Areas with
the least uncertainty are those with a large number of recent surveys with
relatively homogenous results, whereas greater uncertainty would be found in
places with sparse or old surveys with ranges of different observed PRs.
To model a global endemicity surface of P. vivax malaria, an MBG framework that had been successfully employed for falciparum malaria (Hay
et al., 2009; Gething et al., 2011a) was used following modifications made to
accommodate biological features unique to P. vivax.The modelling methods
incorporate surveys from a wide time period such that older surveys are
given less weight than recent ones. The environmental covariates included
were those that had an a priori expectation to affect malaria transmission
intensity. These were urban areas defined by the GRUMP urban extent
product (Balk et al., 2006; CIESIN/IFPRI/WB/CIAT, 2007), a long-term
average vegetation index product used as a proxy for available moisture for
vector reproduction and survival (Hay et al., 2006; Scharlemann et al., 2008),
and the temperature suitability index derived from the model described
above, which identifies areas suitable for transmission based on the requirements of vector survival and sporogony (Gething et al., 2011b).
PR data were standardised by age because of variation in infection rates
observed in different age groups. It is often observed that malaria prevalence rises rapidly in infancy before reaching a plateau in early childhood
and declining through adolescence and adulthood. This phenomenon was
modelled using a previously described framework (Smith et al., 2007) to
standardise for the prevalence variability among age groups. The model was
informed with finely age-stratified PvPR surveys to represent vivax-specific
age profiles (Mueller et al., 2009b; Lin et al., 2010) and was used to convert
all the observed survey prevalence values to standardised age-independent
values for use in the MBG modelling. Predictions were made for all-age
prevalence estimates for individuals aged one to 99 years (PvPR1-99). Children aged <1 year were not included because of the potential confounding
effect of maternal antibodies, but all other ages were included.This deviated
from the method of using the 2- to 10-year cohort for falciparum malaria
(Guerra et al., 2007; Gething et al., 2011a), because all age ranges are typically sampled for P. vivax, which is found at relatively lower prevalence rates.
To determine the endemicity of P. vivax, it was also important to
incorporate Duffy negativity into the modelling framework because of
the refractory nature of the phenotype to the parasite. The map of Duffy

The Global Public Health Significance of Plasmodium vivax

91

negativity described above informed the model of the fraction of Duffynegative individuals in the population at each pixel of the predicted surface. The parasite endemicity prediction could be made, therefore, from the
vivax-susceptible or Duffy positive portion of the population. This meant
that the proportion of PvPR could not exceed the percentage of the population who were Duffy positive and that predictions in data-sparse portions
of Africa could borrow strength from the Duffy negativity surface because
estimates were limited to a more restricted range of potential outcomes.
The endemicity surface that results from the MBG modelling framework described is a 5 × 5 km grid of predictions for PvPR1–99 within
the limits of stable P. vivax transmission. For practical reasons, and because
areas endemic for P. vivax have distinct ecological, entomological and epidemiological characteristics, the P. vivax endemic world was divided into
four regions: the Americas, Africa+, Asia and Asia-Pacific. Separate models
were fitted to each region so that a PvPR1–99 estimate averaged across the
12 months of 2010 was found. The endemicity map was created by using
the mean of each posterior distribution as a point estimate and uncertainty
was shown as the ratio of the posterior distribution IQR to its mean. The
IQR was found to express the precision with which the PvPR1–99 values
were predicted. Calculation of the ratio of the IQR of each posterior distribution to its mean generated an index that demonstrated how the model
performance varied with data density in different locations. This index was
also weighted by population density to generate a map to show where high
levels of uncertainty may be operationally significant.

6.3. The Refined Population at Risk of P. vivax
The various data sources described above were combined to produce the
final spatial limits map (Fig. 1.10A6–D6). After the implementation of
MBG modelling, some of the regions that were estimated as being within
the limits of stable transmission were downgraded to unstable transmission.
If the model outputs of PvPR were extremely low due to a large abundance
of surveys reporting zero infections in that area or, in Africa, because of
high Duffy negativity, a decision rule was applied such that pixels that were
predicted with high certainty (probability >0.9) to be less than 1% PvPR
were reassigned as unstable.
The PAR of P. vivax malaria was estimated using the constrained limits
of infection and population values for 2010 projected from the year 2000
GRUMP beta version population counts. The result was a 1 × 1 km spatial grid of population surface of the number of people living at stable or
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unstable risk in each country as well as surface area of the regions at risk.The
population surface, along with uncertainty maps, was also used to calculate
a population-weighted index of uncertainty. The initial PAR based on the
PvMECs was 5.36 billion individuals in a land area of 69 million km2. After
applying the PvAPI data (1.3 billion PAR excluded), temperature suitability
(sporogony duration; 61 million PAR excluded), aridity (32 million PAR
excluded), medical intelligence (713 million PAR excluded) and the Duffy
negativity (768 million PAR excluded) layers, the remaining PAR was 2.49
billion in an area of 44 million km2.This indicates that P. vivax was endemic
across approximately a third of the world’s surface. Half of that area was
found in Africa (51%) and a quarter was in both America (22%) and Asia
(27%). However, high population density in parts of Asia and the large proportion of the protective Duffy-negative phenotype found in African populations, meant that 82% of the 2.49 billion people at risk were in Asia with
the remaining 17% being spread across Asia-Pacific (9%), the Americas (6%)
and Africa (3%). Well over half of the PAR lived in areas of unstable transmission (62%; 1.52 billion) where transmission was very low and unlikely
to exceed one case per 10,000 people per annum. A total of 965 million
people were estimated to be living at risk of stable transmission. The endemicity maps (Fig. 1.3A2–D2) demonstrate that the transmission potential in
and among stable transmission areas may vary greatly, even within relatively
small geographic areas.

6.4. Mapping the Range of Dominant Vector Species
Vector distribution maps have long been used as a tool to aid malaria control globally. Examples of these maps date back to the 1950s and include
vector species maps (May, 1951) and the ecological zones of malaria epidemiology determined by Macdonald based on climatology and known
vector species ranges (Macdonald, 1957). More recent ecological (Mouchet
et al., 2004) and global vector distribution (Kiszewski et al., 2004) maps
have been widely adopted by the malaria research community. A recent
series of publications by MAP has attempted to update malaria vector distribution maps with a comprehensive and extensive evidence base (Hay
et al., 2010c; Sinka et al., 2010a, 2010b, 2011, 2012). There are 465 formally
described species of Anopheles mosquitoes and more than 50 unnamed
species and species complexes (Harbach, 2011). Approximately 70 species
and species complexes have been incriminated to transmit malaria parasites
(Service and Townson, 2002) and of those, 41 have been identified as DVS
(Hay et al., 2010c). Determination of vector dominance is generally based
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on factors that increase overall vectorial capacity (Takken and Lindsay, 2003),
including abundance, propensity for feeding on humans and the mean adult
longevity (to determine if the species lives long enough to transmit the
parasite) (Hay et al., 2010c). In the process of determining vector dominance, it was noted which anophelines may have the potential to transmit
P. vivax. A literature search of ‘vivax’ and the Anopheles species name was
performed to identify evidence supporting wild transmission of the vivax
parasite. The list of the Anopheles species, species complexes and groups as
well as the evidence gathered regarding the potential for transmission of
P. vivax are shown in Table 1.2.
To predict the geographic range of the 41 DVS of malaria, known
occurrence points, expert opinion maps, ecological data and modelling
techniques were applied. To begin, 15,837 occurrence records from 4800
sources were acquired from systematic searches of formal and informal literature sources and compiled into a comprehensive database (Hay et al.,
2010c; Sinka et al., 2012). Expert opinion (EO) maps were then digitized
from exhaustive searches of published maps, which are referenced in detail
elsewhere (Sinka et al., 2010a, 2010b, 2011), and refined by consultation
with a TAG. A suite of environmental and climatic variables known to shape
vector distribution landscapes (such as elevation, land surface temperature
and precipitation) were also included in the database (Sinka et al., 2010b).
BRT modelling methodology (Elith et al., 2008) was applied to generate a
predicted distribution map for each DVS. Distributions were generated for
nine species/species complexes in the Americas; 13 for Africa, Europe and
the Middle East; and 19 in Asia, 14 of which were in Asia (five were only in
Asia), and 16 in Asia-Pacific (three were only in Asia-Pacific). Information
was also gathered regarding the bionomics of the DVS, which greatly affects
the potential impacts of common malaria interventions such as ITNs and
IRS. Behaviours that were searched for and catalogued by species included
larval site and habitat types, and adult resting and biting behaviours.
The predicted ranges of the DVS varied greatly across the regions, with
relatively straightforward vector profiles in the Americas and Africa and very
complex vector distributions across Asia. The distribution maps illustrate a
probability of occurrence, but do not indicate the predicted prevalence. A
positive (coloured) pixel does indicates that the probability of occurrence
is >0.5 (>0.5 and ≤1.0) and that a negative pixel (not coloured/grey) represents a probability of occurrence <0.5 (0–0.5). The regional maps shown
here are generated from an amalgamation of individual DVS distribution
maps. The TAG identified the top three DVS per country (if the country
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had more than three DVS) and ranked the DVS by their importance.Where
there was great variation within countries (e.g. Indonesia), more detailed
spatial information regarding the DVS was gathered. The rankings were
then used to determine the order in which the species-specific distribution
maps were layered to generate global-scale maps for the Anopheles vectors
of greatest public health importance.

LIST OF ABBREVIATIONS
ACT Artemisinin-based combination therapy
ADMIN Administrative unit
Africa+ Africa,Yemen and Saudi Arabia
Asia Mainland Asia excluding the Malaysian Peninsula
Asia-Pacific The Malaysian Peninsula and the islands of Asia and the Pacific
CSE Asia Central and South East Asia
DVS Dominant vector species or species complexes
ELISA Enzyme-linked immunosorbent assay
G6PD Glucose-6-phosphate dehydrogenase
GRUMP Global Rural-Urban Mapping Project
IQR Inter-quartile range
Lao PDR Lao People’s Democratic Republic
Korea DPR Democratic People’s Republic of Korea
MAP Malaria Atlas Project
MBG Model-based geostatistics
MCMC Markov chain Monte Carlo
PAR Populations at risk
PvAPI P. vivax annual parasite incidence
PvMEC P. vivax malaria endemic country
PvPR P. vivax parasite rate
PvPR1–99 P. vivax parasite rate in 1–99-year olds
RDT Rapid diagnostic test
s.l. sensu lato
s.s. sensu stricto
TAG Technical advisory group
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